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INTRODUCTION 
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HOST DEFENCE AGAINST P.CARINII 
Pneumocystis carinii (P.carinii) is the major causative organism of opportunistic pneumo­
nia in patients with the acquired immunodeficiency syndrome (AIDS), and an important 
pathogen in other immunocompromised patients. The major predisposing condition is 
impaired cellular immunity as induced by immunosuppressive drugs such as corticoste­
roids, protein malnutrition and primary immunodeficiency diseases. Animal experiments 
show the critical role of CD4+ T-lymphocytes in protection against P.carinii. [1,2]. 
Antibodies have been shown to play some role in host defenses against P.carinii [3-5]. 
Knowledge of other components of the host defense system is limited but there is 
evidence that macrophages can phagocytose and kill P. carinii, and that neutrophils are 
present in higher numbers in broncho-alveolar lavage fluid (BAL) in severe P.carinii 
pneumonia (PCP) [6,7]. Cytokines are involved as soluble mediators in the host defense 
against P.carinii, but their exact role in the infection remains to be determined. P.carinii 
was shown to stimulate production of tumor necrosis factor-α (TNF-a) by alveolar 
macrophages in-vivo and in-vitro [8-14]. Although in-vitro studies suggest that P.carinii 
possesses binding sites for TNF-a, it is controversial as to whether TNF-a is capable of 
directly killing P.carinii [8,15-17]. Nevertheless TNF-a and interleukin-lß (IL-lß) are 
considered to be important for the clearance of P.carinii in mice, while interleukin-6 (IL-
6) regulates pulmonary inflammation and antibody response during resolution [18-20]. 
Increased TNF-a secretion and upregulated TNF-mRNA expression in alveolar macropha-
ges have been shown in mice depleted of CD4+ Τ cells and infected with P.carinii [9]. 
In corticosteroid induced PCP in Wistar rats, TNF-a concentration in BAL increases 
during the first weeks of recovery and is inversely correlated with P.carinii cyst count 
[21]. In human immunodeficiency virus seropositive (HIVpos) patients with PCP, 
spontaneous TNF-a production by alveolar macrophages and to a lesser extent by 
peripheral blood monocytes is markedly increased [13]. 
Since cytokines mainly work in a paracrine or autocrine way, it can be expected that in a 
focal infection such as pneumonia, the cytokine pattern at the site of infection differs from 
the pattern in the circulation. In the lung, between the alveolar space and the blood 
circulation, there is a third compartment, the interstitial tissue. It is conceivable that even 
within the lung, cytokine profiles will be different in the various compartments, as 
differences in microenvironment have profound effects on the phenotype and capabilities 
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of macrophages, the main producers of TNF-a and IL-Iß. 
PCP only develops in immunocompromised hosts. Immune deficiencies per se influence 
cytokine patterns; corticosteroids suppress pro-inflammatory cytokine production, while 
HIV infection is often associated with increased pro-inflammatory cytokine production 
[22-36]. Consequently, cytokine profiles in immunocompromised patients with PCP will 
be attributable to either PCP and/or the underlying immunosuppression. 
OUTLINE OF THIS THESIS 
The objective of this thesis was to increase insight in the role of cytokines in the pathoge-
nesis of PCP by exploring the compartments in which the cytokine responses take place. 
Therefore, we present data on cytokine profiles (in-vivo concentrations and ex-vivo 
production) in various compartments in animals and humans with different underlying 
immunodeficiencies. We studied, in plasma as well as in BAL, concentrations of immuno-
reactive IL-lß, TNF-α, IL-6 and their inhibitors, IL-1 receptor antagonist (IL-1RA) and 
the soluble TNF receptors (sTNF-R) in 2 patient groups, consisting of immunosuppressed 
HIV-seronegative (HIVneg) patients and HIVpos patients with PCP. In addition, im-
munoreactive IL-lß and bio-active IL-6 and TNF-a were measured in corticosteroid-
treated rats with PCP. In the rats, we studied cytokine profiles in BAL, plasma, and lung 
homogenates. Ex-vivo production by alveolar cells and in whole blood cultures were stu-
died in patients as well as in rats. 
To gain more insight in the role of cytokines during the course of PCP parameters were 
defined for P. carinii load and host inflammatory responses in corticosteroid-induced PCP 
in rats. In chapter two we present the rat PCP model. Whether P.carinii is able to 
stimulate in-vitro production of cytokines is explored in chapter three. The question of 
cytokine profiles in rats, HIVneg and HIVpos patients is addressed in respectively chapter 
four, five and six. Chapter seven explores the possible therapeutic role of local TNF 
modulation in experimental PCP. In the general discussion, in chapter eight, we summa-
rize the common features of cytokine profiles in the different PCP models and present a 
hypothesis, explaining the differences between local and systemic cytokine profiles in 
PCP. 
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ABSTRACT 
To study the effect of new therapeutic strategies, we developed an animal model to 
monitor course and severity of experimental Pneumocystis carinii pneumonia (PCP) in 
rats. Pneumocystis carinii (P.carinii) density scores in Giemsa stained impression smears 
were used to follow P.carinii load. '"Indium ('"In) labelled IgGscintigraphy (IgG-scan) 
and biodistribution, histology of paraffine embedded tissue sections, lung/body weight 
(L/B wt) ratio and cell count and differentiation of broncho-alveolar lavage fluid were 
used as parameters of host inflammatory response. 
Results: statistically significant differences in L/B wt ratio, number of neutrophils in BAL 
fluid, P.carinii density score, histologic extend of inflammation and '"In-IgG accumu-
lation in the lung were seen between the rats sacrificed at various timepoints. lllIn-IgG 
accumulation in the lung correlated well with L/B wt ratio, with P.carinii density score 
and correlated moderately with number of neutrophils in BAL fluid and with histologic 
extend of inflammation. 
INTRODUCTION 
Pneumocystis carinii pneumonia (PCP) is an important infection, causing morbidity and 
mortality in immunocompromised patients, especially AIDS patients [1]. Adverse 
reactions to effective drugs such as trimethoprim-sulfamethoxazol, clindamycine, 
pentamidine and trimetrexate have prompted a search for alternative therapeutic strategies 
[2]. 
To study the effect of new therapeutic strategies, we developed an animal model to 
monitor course and severity of experimental PCP in rats. The outcome of infection is 
decided by the balance between the offensive power of microbial pathogens and the 
defenses of the host. Sometimes the host succumbs because of an overwhelming invasion 
of microorganisms, at other times death is due to an overwhelming inflammatory 
response. To evaluate therapeutic strategies, it is therefore important to monitor the 
growth of the micro organisms as well as the magnitude of the host response. P.carinii 
density scores in Giemsa stained impression smears are a good method to follow P.carinii 
load, but do not give information on the inflammatory response of the host [3]. Histology 
of paraffin embedded tissue sections gives a good impression of the extent of infiamma-
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tion, but is time consuming and difficult to quantify [4,5]. 
'"Indium ( i nIn) labelled IgG scintigraphy (IgG-scan) and biodistribution are effective 
methods to identify local inflammation in PCP [6,7]. These methods detect disease 
activity early in the course of the infection and are easy to quantify. 
We describe a model to monitor course and severity of experimental PCP in rats, using 
lllIn-IgG biodistribution. 
MATERIALS AND METHODS 
Animal model 
Four to six weeks old, female Spraque-Dawley rats, with bodyweights between 150-175 
gram, were immunosuppressed with weekly injections of 25 mg hydrocortisone subcuta-
neously and a 8% protein restricted diet. Amoxicylline (lmg/ml) was added to their 
drinking water to prevent bacterial infections. PCP was induced by close cohabitation 
with P.carinii infected rats. Viral co-infection was excluded by regular serological 
screening on common rodent viruses. Bacterial or fungal co-infection was excluded by 
microscopic examination of Giemsa stained smears of the cut surface of the lung. Body 
weight was measured weekly. 
Radiopharmaceutical and imaging protocol 
Diethylenetriaminepentaacetic bicyclic anhydride (bicyclic DTPA) was conjugated to HIV-
and HBsAg-negative, human, nonspecific, polyclonal IgG (Sandoglobulin, Sandoz AG, 
Neurenberg, FRG) according to the method described by Hnatowich and colleagues (8). 
The conjugated solution was sterilized by membrane filtration with a 0.4/*m millipore 
filter and aliquots of 0.5 ml were radiolabeled with '"In (Indium chloride, Amersham 
International Ltd., Buckinghamshire, UK) via citrate transchelation. Radiochemical purity 
was determined by ITLC-SG chromatography (Gelman Laboratories, Ann Arbor, MI 
USA) with 0.1 M citrate (pH=5) as the solvent. Labeling efficiency was always higher 
than 95%. 
For imaging purposes, a dose of approximately 10 μ% of IgG-labeled with 6 MBq '"In 
was injected intravenously via the tail vein 48 hours before IgG-scanning. Scintigraphic 
images were obtained with a Siemens Orbiter gamma-camera connected to a Scintiview 
image processor (Siemens Inc., Hoffmann Estates, IL). All images were collected in digi­
tal format. A quantitative analysis of intrapulmonary accumulation of '"Indium was 
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calculated, using regions of interest in sequential IgG scans. The mean lung activity was 
normalized to background by dividing lung by head activity of the animals. 
For biodistribution studies, lung and muscle activity was measured 48 hours after 
injection of 10 μg IgG labelled with 1 MBq u l In by counting the tissue samples in a shiel­
ded well-type gamma counter. To correct for radioactive decay and permit calculation of 
the uptake of the radiopharmaceuticals in each organ as a fraction of the injected dose, 
aliquots of the respective dose were counted simultaneously. The activity measured in 
tissues was expressed as percentage of injected dose per gram. Lung to muscle ratios 
were calculated. 
Study design 
In these studies a relative large number of rats is needed because in the steroid induced 
rat model a 15-25% mortality due to other causes that PCP has to be anticipated. In addi­
tion the severity of PCP may vary between rats. 
In experiment A, we followed 50 individual rats longitudinally. IgG-scans were made at 2 
week intervals. The animals were followed untili death, whereafter the lungs were 
removed and the lung weight measured. Giemsa stained impression smears of the cut 
surface of the left lobe were examined microscopically to determine numbers of P.carinii. 
In experiment B, a transversal study on 32 rats, we compared lung/body weight ratio, 
number of broncho-alveolar cells, P.carinii density score, inflammation score and " Ί η -
IgG uptake in the lung as parameters during development of PCP. Every 2 weeks 5-8 rats 
were given ulIn-IgG intravenously. Two days later the animals were killed by bleeding 
and a broncho-alveolar lavage (BAL) was performed [9]. Total lung weight before the 
BAL and weights of the separate lung lobes after BAL were measured. The uptake of 
mIn-IgG in the right upper lung lobe and in a normal calf muscle sample for reference 
were measured. P.carinii density was assessed in Giemsa and silver stained impression 
smears, extend of inflammation in paraffin embedded tissue sections and cell count and 
differentiation in cytocentrifuged BAL fluid samples. The logarithmic P.carinii density 
score was assessed according to the method of Bartlett [4]. In short, 2 individuals exami­
ned the slides, scoring at least ten fields per slide according to the following scheme: in 
one lOOOxfield > 100 cysts =5, 11 to 100=4, 1 to 10=3, 2 to 9 in 10 lOOOxfield =2, 1 
in 10 fields = 1 , and 0 in 50 fields =0. 
Extent of inflammation in the paraffin embedded lungsections was assessed by 2 exami­
ners and scoring was defined as follows:0= normal lung histology, 1= mild alveolar and 
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Fig. 1. Serial '"Indium-IgG scans and lung lo-head ratios in Ρ 
carimt pneumonia in rats Ν В Lung-to-head ratio = activity ot 
chosen region of interest in the lung divided by activity of chosen 
region of interest in the head 
Lung/body weight ratio 
«••fa 0 w*«k 2 »мк 4 амк Б 
Number of neutrophils in 
broncho-alveolar fluid. 
a>Jt»M 
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broncho-alveolar fluid 
i 0 w««k 2 »*«k 4 »**k Б 
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Inflammation score 
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Indium uplake in the lung 
lung/muscle ratio 
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В •·*> ' J UH 
FÍR. 2. Parameters ol inflammation in the course ol Ρ uu mu 
pneumonia in rais The appearance ol similar signs ( "" • and ,) 
above ine columns denotes signilicani différences (/'<0 OS) at the 
time point-, in question (ANOVA) 
interstitial cellular infiltrate with less than 
10% of the alveoli involved, 2= moderate 
interstitial and alveolar cellular infiltrate, 
with between 10-75% of the alveoli in-
volved and 3= severe interstitial and al-
veolar cellular infiltrate with more than 
75% of the alveoli involved. 
Statistics 
The mean lung-to-head ratio at 0, 2, 4 and 
6 weeks after start of the PCP inducing diet 
and corticosteroids were compared using a 
Student's T-test. Lung/body weight ratio's, 
number of macrophages and neutrophils in 
BAL fluid, P.carinii density scores, his-
tology inflammation scores and "'Indium 
uptake were evaluated as parameters for 
PCP severity using a one way analysis of 
variance (ANOVA). Linear regression 
coefficients were calculated. 
The study was approved by the University 
Committee on Animal Experiments. 
RESULTS 
Serial IgG scintigraphy 
In experiment A, 8 rats (16%) died in the 
first 6 weeks or before an '"In-IgG scan 
could be made, while 84% of the animals 
died with severe PCP, 6-11 (median 8) 
weeks after start of the experiment. From 2 
weeks onward a steady increase of accumu-
lation of radioactivity in the lungs was 
seen. The accumulation of radioactivity in 
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the head remained the same during the course of PCP. Figure 1 shows a typical example 
of serial scans and lung-to-head ratio in one rat. Although at visual interpretation, 
pulmonary uptake seemed to increase at the various timepoints, mean lung-to-head ratio at 
the various time points (0, 2, 4 and 6 weeks) were not statistically different. 
Results of experiment В are presented in figure 2. Nine animals died before termination 
of the experiment or were excluded because of bacterial or fungal contamination. In the 
remaining 23 animals statistically significant differences in lung/body weight (L/B wt) 
ratio, number of neutrophils in BAL fluid, P.carinii density score, histologic extend of 
inflammation and mIn-IgG accumulation in the lung were seen between the rats sacrificed 
at various timepoints. The mean lllIn-IgG accumulation in the muscles was not different 
at the various time points. inIn-IgG accumulation in the lung correlated well with L/B wt 
ratio (correlation coefficient (cc) 0.8, ρ<0.0001), with P.carinii density score (cc 0.8, 
ρ<0.0001) and correlated moderately with number of neutrophils in BAL fluid (cc 0.6, 
p=0.008) and with extend of inflammation (cc 0.6, p=0.0026). It did not correlate with 
number of macrophages in BAL fluid (cc -0.38, p=0.149). 
DISCUSSION 
This study shows that IgG-scans and "'Indium biodistribution are sensitive and quantitati­
ve methods to assess the severity of PCP. An early event in PCP is the alveolar-capillary 
leak, which follows attachment of P.carinii to the type 1 pneumocyte and its subsequent 
decrease of surface glycocalix [10]. As shown recently "Ίη-IgG scintigraphy visualises 
this leak. The mechanism by which '"In-IgG accumulates in focal sites of infection and 
inflammation was recently elucidated by Claessen et al [11]. It was shown that '"In-IgG 
enters the inflammatory site via an increased vascular permeability. In the inflammatory 
field, the Indium appears to be split off from the IgG and remains at that site. The IgG 
has been shown to leave the inflammatory site. Our data corroborate the findings by Fish-
man et al. in rat PCP and by Buscombe et al. in human PCP, that serial IgG scans are 
useful to monitor the course of PCP [6,12,13]. The present study gives a more precise 
quantification of the inflammatory parameters and demonstrates that the various parame­
ters correlate with one another. Quantitative analysis of the inflammation can be done by 
comparing the ratio of lung activity to that of another (non involved) part of the body and 
was shown to be a reliable quantitative tool in human respiratory infections [10]. In rat 
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PCP however, this analysis in sequential scans was hampered by the difficulty to draw 
regions due to interfering blood pool, i.e. heart activity. The tiny lung area of the rat pre-
cluded reliable assesment and most probably caused the inability to show statistically 
significant increases in lung activity. However '"Indium biodistribution proved to be a 
good quantitative tool to monitor the magnitude of the alveolar-capillary leak. This 
parameter significantly increases at each 2-week interval and correlates well with various 
other parameters of severity of the infection. Lung/body weight ratio and '"Indium uptake 
both mirror the magnitude of alveolar-capillar leakage and correlate well with one 
another. 
We could confirm earlier reports that the number of neutrophils increase during the 
course of a PCP and found that it correlates well with severity of infection. 
In PCP, P.carinii density score in Giemsa stained impression smears, have been shown a 
reliable and reproducable method to assess P.carinii load [2]. In the present study, 
P.carinii density score increases gradually during infection and the score was significantly 
different at the time points chosen (0, 2, 4 and 6 weeks). 
Histology of paraffin embedded tissue sections gives a good impression of the extend of 
inflammation (the host response), but it is time consuming and difficult to quantify. The 
histological scoring system showed, in our hands, considerable intra- and inter-individual 
variation, especially early in the infection (data not shown). As the infection is patchy in 
that period, sampling errors are probably partly responsible. Difficulties in quantification 
of the inflammation, the work and time needed to prepare and evaluate the tissue sections 
make this method less suitable to monitor the magnitude of host response in PCP. 
In conclusion, we showed that combining data on lung/body weight ratio, number of 
neutrophils in BAL fluid, P.carinii density score in Giemsa stained impression smears and 
"4ndium-IgG biodistribution in rat PCP is a good way to monitor course and severity of 
PCP. Future studies have to show whether this method is useful to evaluate therapeutic 
strategies in PCP. 
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INTRODUCTION 
Induction of cytokine responses in cells of the defense system is an important event in 
cellular immunity and inflammation. Since TNF-α, IL-lfl and IL-6 seem to play a role in 
the defense against PCP, we studied the capacity of P.carinii cysts to induce in-vitro 
production of these cytokine in peripheral blood mononuclear cells and alveolar cells [1-
4]. 
MATERIAL AND METHODS 
P.carinii cysts and trophozoites were incubated with peripheral blood mononuclear cells 
(PBMC's) and alveolar cells (obtained by bronchoalveolar lavage) from 8 healthy volun­
teers for 24 hours. The P.carinii cysts and trophozoites were isolated on a discontinuous 
Percoli gradient (Sigma Chemical) from enzyme treated (0.2% collagenase and 0.2% 
hyaluronidase, Sigma) lungs of P.carinii infected rats and a HIV seronegative patient. The 
cultures were carried out in duplicate with polymyxine В (Sigma, final concentration 1 
Mg/ml) to neutralize the possible presence of contaminating lipopolysaccharide (LPS). 
Parallel cultures of the same cells were performed without any additions, with LPS (final 
concentration 10 /xg/ml) and with supernatants of uninfected rat lung preparations. 
Immunoreactive TNF-a, IL-Iß, and IL-IRA were measured in the supernatants, using 
specific radio-immuno assays (RIA) [5,6]. 
RESULTS AND DISCUSSION 
LPS-stimulated cultures of PBMC's and alveolar cells showed a significant increase in 
cytokine production as compared to unstimulated cultures. Cytokine production by 
PBMC's and alveolar cells co-cultured with P.carinii cysts was not different from the 
production of cells incubated with uninfected lungs (table 1). 
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Tabel la. In-vitro cytokine production by alveolar cells 
No additions 
LPS, ΙΟμ^τηί 
uninfected rat 
lung 
Human 
P.carinii 
Rat 
P.carinii 
IL-Iß, pg/ml 
<80 
(< 80-2280) 
3580* 
(360-5440) 
<80 
(< 80-80) 
<80 
(< 80-240) 
<80 
(< 80-100) 
TNF-a, pg/ml 
900 
(390-12.060) 
22.700 * 
(5000-> 33.000) 
1300 
(660-4100) 
1430 
(680-3780) 
1680 
(< 80-3080) 
IL-1RA, ng/ml 
6.5 
(< 0.8-9.7) 
10.2 
(1.4-17.3) 
3.5 
(2.6-7.8) 
4.3 
(1.8-9.2) 
6.2 
(0.8-9.0) 
Tabel lb. In-vitro cytokine production by peripheral blood mononuclear cells. 
No additions 
LPS, lO^g/ml 
uninfected rat 
lung 
Human 
P.carinii 
Rat 
P.carinii 
IL-Iß, pg/ml 
<80 
(< 80-160) 
3760 * 
(1720-
> 25.000) 
<80 
(< 80-740) 
<80 
(< 80-80) 
<80 
(<80) 
TNF-a, pg/ml 
600 
(< 80-1420) 
2360* 
(440-9620) 
380 
(< 80-820) 
600 
(100-940) 
320 
(80-820) 
IL-1RA, ng/ml 
1.2 
(< 0.8-6.2) 
3.6 
(0.8-11) 
1.1 
(< 0.8-2.4) 
0.95 
(<0.8-l.l) 
1.4 
(<0.8-3.1) 
Tabel 1. In-vitro cytokine production by alveolar cells and peripheral blood mononuclear cells (PBMC's) 
Trom 8 healthy volunteers. Data are given in median and range. 
* Denotes statistical significance (P<0 05, Wilcoxon rank test) from unstimulated controls. All cell 
suspensions contained 0.5xl06 cells/ml, all P.cannn cysts suspensions contained 106 cysts /ml. To avoid the 
effects of contaminating lipopolysacchande (LPS), Ρ carinii cysts and uninfected rat lung suspension were 
diluted in medium containing lftg/ml of polymyxin B. 
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The high production of cytokines in the LPS-stimulated cultures proved that the cells in 
our system were viable and able to produce cytokines. P.carinii organisms however, 
could not stimulate the production of TNF-a, IL-lß and IL-1RA by human PBMC's and 
alveolar cells. Helmke and Hidalgo also reported that rat alveolar macrophages failed to 
produce TNF-a when exposed in-vitro to P.carinii organisms [7], but several others did 
report in-vitro TNF-a release in similar experiments (1-4). As the source and number of 
P.carinii used, the cell concentrations and the concentration of polymyxine В in our 
experiments are similar to the conditions used by Tamburrini and Pesanti we cannot 
explain the discrepancies. These results may be explained by differences in cell selection 
(unselected alveolar cells versus adherent cells), culture conditions and the presence or 
abscence of contaminants in the P.carinii preparations. 
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ABSTRACT 
To gain more insight in the role of cytokines in Pneumocystis carinii pneumonia (PCP) 
we followed pro-inflammatory cytokine profiles in rats with steroid induced PCP at 2-
weekly intervals. The cytokines measured were immunoreactive interleukin-1 (IL-1) and 
bioactive interleukin-6 (IL-6) and tumor necrosis factor-α (TNF). In-vivo cytokine 
concentrations were determined in 3 compartments, i.e. BAL fluid, lung homogenates and 
plasma. Lipopolysaccharide (LPS)-stimulated cytokine production by alveolar cells and in 
whole blood cultures was measured ex-vivo. Pneumocystis carinii (P.carinii) load and 
host inflammatory response, as determined by lung/bodyweight ratio and '"-IgG-Indium-
biodistribution were monitored throughout developing PCP. 
IL-lß was elevated in lung homogenates (600, range < 20-1260 pg/ml) and IL-6 in BAL 
fluid (48, range <20-l 15 pg/ml), whereas the pro-inflammatory cytokine concentrations 
were not increased in plasma. Thus in rats with PCP elevated pro-inflammatory cytokines 
concentrations were found to be restricted to the lung compartments. 
Corticosteroids did not significantly influence cytokine concentrations, but showed pro-
found inhibitory effects on ex-vivo cytokine production. The LPS-stimulated cytokine 
production by alveolar cells gradually decreased during the 6 weeks after start of the 
steroid injections, while the production in whole blood cultures was immediately and 
completely suppressed. 
INTRODUCTION 
Pneumocystis carinii pneumonia (PCP) is a common pathogen in immunocompromised 
hosts. Cellular immunity, in particular CD4+ lymphocyte dependent mechanisms, are 
considered important host defense mechanisms against P.carinii [1,2]. Evidence to date 
indicates that cytokines, the intercellular messengers involved in many inflammatory 
processes, also play a role in PCP. In-vitro studies show that P.carinii possesses binding 
sites for tumor necrosis factor-a (TNF) and that this cytokine is capable of killing 
P.carinii [3-5]. In mice TNF and interleukin-1 ß (IL-lß) are critical in the clearance of 
P.carinii, and interleukin-6 (IL-6) was found to regulate pulmonary inflammation and 
antibody response during resolution of PCP [6-8]. P.carinii has been reported to stimulate 
in-vivo and in-vitro production of TNF by alveolar macrophages [9-14]. 
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Corticosteroids downregulate pro-inflammatory cytokine production and increase the risk 
for PCP in patients and in animal models [15-18]. We previously described cytokine 
patterns in immunosuppressed HIV seronegative (HIVneg) and HIV seropositive (HIVpos) 
patients with PCP [19,20]. In these studies corticosteroids did not seem to influence 
plasma cytokine concentrations, but we observed strong downregulation of cytokine 
production in whole blood cultures of patients with severe PCP, who had been given 
corticosteroids. However, since severe infection in itself can also downregulate pro-
inflammatory cytokine production, it was impossible to assess the relative contribution of 
corticosteroids and P.carinii pneumonia to the measured cytokine profiles [21,22]. 
This prompted us to perform cytokine studies in immunosuppressed rats infected with 
P.carinii under carefully controlled experimental conditions. 
MATERIAL AND METHODS 
Animal model 
Four to six weeks old, female Spraque-Dawley rats, with body weights between 150-175 
gram, were immunosuppressed by weekly subcutaneous injections of 25 mg hydrocortiso-
ne and a 8% protein restricted diet (Table 1.). Amoxicilline (lmg/ml) was added to the 
drinking water to prevent bacterial infections. PCP was induced by close cohabitation 
with P.carinii-infected rats (PCP rats), thereby exposing them passively to P.carinii 
which is transmitted by air. Similar to other investigators, we lost 15-25% of the rats 
before endpoints were reached [23]. Of the rats who survived 4 weeks cohabitation with 
infected littermates, more than 95% developed PCP. As we have shown before, the 
secondary rats develop a consistent and comparable PCP and the level of infection is 
standardized by P.carinii density score (see below) Barrier sustained rats (housed at 
another level of the animal quarters, in cages covered with airfilters) were subjected to 
the same immunosuppressive regime without development of PCP (steroid rats). Control 
rats were not immunosuppressed, barrier sustained and free of PCP (healthy rats). Viral 
co-infection was excluded by regular serological screening for common rodent viruses. 
Bacterial or fungal co-infection was excluded by microscopic examination of Giemsa-
stained smears of the cut surface of the lung. Body weight was measured weekly. 
At 2 weekly intervals after start of the immunosuppression, "'Indium-IgG (n,In-IgG) 
intravenously was given to a group of PCP, steroid and healthy rats, as described 
elsewhere [23]. Two days later the animals were killed by bleeding and a broncho-alveo-
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lar lavage (BAL) was performed [24]. Total lung weight before the BAL and weights of 
the separate lung lobes after BAL were measured. The uptake of "Ίη-IgG was measured 
in the right upper lung lobe and in a normal calf muscle sample for reference. P.carinii 
density was assessed in Giemsa and silver-stained impression smears and expressed in the 
logarithmic P.carinii density score as described by Bartlett [16]. Blinded to the condition 
of the animals, two individuals examined the slides, according to the following score: in 
one lOOOxfield > 100 cysts =5, 11 to 100=4, 1 to 10=3, 2 to 9 in 10 lOOOxfield =2, 1 
in 10 fields =1, and 0 in 50 fields =0. 
Processing BAL fluid and lung tissue 
Immediately following BAL the fluid was centrifugea at SOOg for IS minutes. Supernatant 
was removed, aliquoted and frozen at -80°C. The pellet was resuspended in Dulbecco's 
modified Eagle's medium at a concentration of 0.5 X 10' viable macrophages per ml; 
viability was assessed by trypan blue dye exclusion. This was subsequently incubated in 
2-ml closed polystyrene tubes (Greiner, Alphen, The Netherlands) in the presence or 
absence of lipopolysaccharide (LPS, E Coli serotype 055;B5, Sigma) at a final concentra­
tion of 10 Mg/ml. All incubations were done at 37° С for 24 hours in a C0 2 incubator. 
Following incubation the tubes were centrifuged at 1200g for 10 minutes and the 
supernatant and cell pellets separately frozen at -80°C until cytokine analysis. The left 
upper lung lobe was homogenized in a blender and sonificated in a 10 ml PBS solution of 
protease inhibitors, containing 2 mMol Phenylmethylsulfonyl fluoride, lmg/L antipaine, 
lmg/L aprotinine, lmg/L Ieupeptine and lmg/L pepstatin. The sonificated homogenate 
was centrifuged at 1200g for 15 minutes and the supernatant frozen until cytokine 
analysis. 
Processing whole blood 
Blood was collected aseptically into three 2-ml polystyrene tubes, containing 20 μ\ 
héparine (Heparine sodium 5000 lU/ml, LEO Pharmaceuticals BV, Weesp, The Nether-
lands). One tube was immediately centrifuged at 1250g for 10 minutes, the plasma 
transferred to a polypropylene tube and frozen at minus -80 "C until cytokine analysis. To 
one of the two remaining tubes LPS was added (final concentration 10 ¿xg/ml) to stimulate 
cytokine production. This tube and the third tube were incubated at 37 °C for 24 hours. 
After incubation the tubes were centrifuged and the supernatant frozen at -80°C. 
28 
Cytokine assays 
Plasma and BAL samples were analyzed by means of bio-assays for IL-6 and TNF 
respectively and ELISA for IL-lß. IL-6 was measured using the B9 hybridoma bio-assay, 
TNF by the L929 cytotoxicity assay [25,26]. For IL-1 we used a specific rat ELISA 
(provided by Dr.S. Poole, National Institute Biological Standards, Hertfordshire, 
England). The detection limit of all three assays was 20 pg/ml. 
Radiopharmaceutical protocol 
"Ίη-IgG scans and biodistribution are sensitive and quantitative methods to assess the 
severity of PCP [23,27,28]]. 'uIn-IgG enters inflammatory sites via an increased vascular 
permeability, whereafter the indium is split off from the IgG and remains at that site. We 
have shown in an earlier report that '"In cumulation in the lung correlates well with 
P.carinii density scores and parameters of host inflammatory responses [23]. IgG 
Diethylene triamine penta-acetic bicyclic anhydride (bicyclic DTPA) was conjugated to 
human, nonspecific, polyclonal IgG (Sandoglobulin, Sandoz AG, Neurenberg, FRG) 
according to the method described by Hnatowich and colleagues [29]. The conjugated 
solution was radiolabeled with '"In (Indium chloride, Mallinckrodt Medical, Petten, The 
Netherlands) via citrate transchelation. Radiochemical purity was determined by ITLC-SG 
chromatography (Gelman Laboratories, Ann Arbor, MI USA) with 0.1 M citrate (pH=5) 
as the solvent. Labeling efficiency was always higher than 95%. 
For biodistribution studies, lung and muscle activity was measured 48 hours after 
injection of 10 /ig IgG labelled with 1 MBq "'In by counting the tissue samples in a shiel­
ded well-type gamma counter. To correct for radioactive decay and permit calculation of 
the uptake of the radiopharmaceuticals in each organ as a fraction of the injected dose, 
aliquots of the respective dose were counted simultaneously. The activity measured in 
tissues was expressed as percentage of injected dose per gram. Lung to muscle ratios 
were calculated. 
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flammation in steroid indu­
ced Pneumocystis carinii 
pneumonia in rats; P.carinii 
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relative lungweight (B) and 
relative uptake of '"Indium-
IgG in the lung (C). Ste­
roid rats (Ι Π ) are rats 
immunosuppressed with 
weekly injections of hydro­
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of PCP. PCP rats ( О ) are 
rats subjected to the same 
immunosuppression regimen 
with severe PCP at week 6. 
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were not immunosuppressed 
and free of PCP. Number 
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Statistics 
Data on P.carinii density score, Lung/body weight ratio and ,n-IgG-Indium uptake were 
normally distributed and are therefore given in means and standard error of the means 
(SEM) and analyzed by Students's t test. Cytokine concentrations and production did not 
follow Gaussian distributions and are therefore given in medians and ranges and analyzed 
with the non-parametric Mann-Whitney test. Lung/body weight ratio's, '"-IgG-Indium 
uptake and the various cytokine concentrations and production capacities were evaluated 
as parameters for inflammation using a one way analysis of variance (ANOVA). Linear 
regression coefficients were calculated. 
The study was approved by the University Committee on Animal Experiments. 
RESULTS 
Development of PCP and host inflammatory responses 
P.carinii density in lungs of rats exposed to P.carinii infected littermates steadily increa­
sed during the 6 weeks after start of immunosuppression (Fig.lA). Similarly, host inflam­
matory reaction, expressed in terms of lung/body weight (L/B) ratio (Fig.IB) and " Ί η -
IgG lung/muscle biodistribution (L/M ratio, Fig. 1С), increased every 2 weeks. Both 
ratios were correlated with the P.carinii density score (r= 0.8, p<0.0001). Although L/B 
ratio of steroid rats also slightly increased over time, the ratio was always higher in PCP 
rats. L/M ratios in PCP rats were significantly higher than in steroid rats or healthy rats 
at week 4 and 6. 
Cytokine concentrations in BAL and lung homogenates 
Immunoreactive IL-lß was present in BAL fluid of healthy rats at concentrations of 280, 
range <20-640 pg/ml (Fig.2A). The median IL-lß concentrations in BAL in steroid and 
PCP rats were lower, these differences were however not significant. 
In lung homogenates of PCP rats IL-lß concentrations at week 4 and 6 were significantly 
higher than in steroid or healthy rats (week 6: 600, range < 20-1260 versus 43, range 
27-320 respectively <20, range < 20-380 pg/ml, ρ < 0.05. Fig.2B). 
Bioactive IL-6 could not be detected in BAL fluid of healthy rats or immunosuppressed 
rats. However, IL-6 was found in BAL fluid of rats with PCP at week 4 and 6 , with the 
highest concentration at week 4 (Fig.2C). Although these IL-6 concentrations were 
relatively low (48, range <20-115 pg/ml), the differences with healthy and steroid rats 
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were significant (ρ <0.05). IL-6 could not be found in lung homogenates of rats in any of 
these group. Bioactive TNF could not be detected in BAL fluid or lung homogenates of 
rats in any group. 
Cytokine concentrations in plasma 
IL-6 was present in plasma (21-136 pg/ml) from 6 of the 19 immunosuppressed rats in 
week 4 and 6 irrespective the presence of PCP. Although IL-6 could not be detected in 
the plasma of healthy rat, the differences between PCP and healthy rats were not signifi­
cant. Bioactive TNF and immunoreactive IL-Iß could not be detected in plasma of the 
rats in any group. 
Ex-vivo cytokine production by alveolar cells 
LPS-stimulated production of IL-lß, IL-6 and TNF gradually decreased over the 6 week 
period in both steroid and PCP rats, with a slower decline in PCP rats (Fig.3). 
At week 4 the production of pro-inflammatory cytokines was higher in PCP than in 
steroid rats, although this difference was only significant for IL-6. In the absence of LPS, 
ex vivo cytokine production of alveolar cells was generally low (<400 pg/ml); however, 
in week 4 significant amounts of IL-6 (747, range 20-2650 pg/ml) and TNF (545, range 
< 20-2400 pg/ml) secretion was found in the non-stimulated culture supernatant in PCP 
rats. 
Ex-vivo production in whole blood cultures 
In healthy rats, LPS-stimulated production of IL-lß was 500, range 200-786 pg/ml and of 
IL-6 2250, range 600-5000 pg/ml. Both in PCP and steroid rats IL-lß and IL-6 producti-
on was almost completely suppressed from week 2 onward (Fig 3D and 3E). 
In the absence of LPS ex vivo production of pro-inflammatory cytokines was around the 
detection limit, with an exception for IL-6 in steroid rats at week 4 and week 6 (150, 
range <20-365 pg/ml respectively 340, range < 20-570 pg/ml). 
Bio-active TNF could not be detected in whole blood cultures. 
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Correlations between cytokine patterns and parameters of inflammation 
Cytokine concentrations in BAL, lung homogenates or plasma did not correlate with the 
other inflammatory parameters. The LPS-stimulated production of TNF and IL-6 by 
alveolar cells in steroid rats was inversely correlated with L/B ratios (r= -0.63, P=0.01 
respectively r= -0.72, p=0.002). There was no correlation with L/M ratios. The LPS-
stimulated production of IL-6 by alveolar cells in PCP rats was inversely correlated with 
L/B ratios (r= -0.58, p= 0.02) as well as with L/M ratios (r= -0.61, P= 0.01). Produc-
tion in whole blood cultures did not correlate with other inflammatory parameters. 
DISCUSSION 
In this study on experimental PCP in rats, pro-inflammatory cytokine concentrations were 
followed in BAL fluid, lung homogenates and plasma and compared with those in rats 
subjected to the same immunosuppressive regime but without PCP (steroid rats) and with 
those of healthy rats. In rats with PCP, elevated pro-inflammatory cytokine concentrations 
were found in the lung compartments at week 4 and 6, i.e., IL-Iß in lung homogenates 
and IL-6 in BAL fluid. Why different pro-inflammatory cytokines are present in the 
different lungcompartments needs further study. The explanation is most likely multifac-
torial and may reflect relative differences in cytokine producing cell populations, presence 
of other inflammatory proteins and presence or absence of surfactant in the different 
lungcompartments. The presence of pro-inflammatory cytokine concentrations in the lung 
is supported by the results obtained with ex vivo production of cytokines. At week 4, 
when the infection is clearly established and all PCP rats have elevated P.carinii-density 
scores, alveolar cells of PCP rats spontaneously produced substantial amounts of IL-Iß 
and IL-6 and their LPS-stimulated production was higher than in steroid rats. This could 
point to activation of these cells in vivo. Previously we observed a similar pattern in 
patients with PCP, showing increased pro-inflammatory cytokine concentrations in BAL 
fluid [19,20]. In HIV-seronegative patients with PCP on longterm corticosteroids, 
immunoreactive TNF was found to be increased in BAL fluid, while in HIV-seropositive 
patients IL-Iß was found to be increased. In this study on rat PCP, we used a TNF bio-
assay and the undetectable concentrations of TNF in BAL and lung homogenates may be 
due to the presence of inhibitors, such as soluble TNF-receptors. A reliable immunoassay 
for rat-TNF was not available to us. Our finding of undetectable bio-active TNF levels in 
whole blood cultures, even following LPS stimulation, differs from the findings of Wright 
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et al.[30]. Differences in animal model (rabbit versus rat) and bio-assay (WEHI versus 
L929 bio-assay) may explain the discrepancy. 
Similar to our data in humans with PCP, plasma concentrations of pro-inflammatory 
cytokines were not elevated in PCP rats, pointing to a compartmentalization of the pro-
inflammatory cytokines in the lungs. One may speculate that the pro-inflammatory 
cytokines are needed in the lung to neutralize P.carinii, whereas the body should be 
protected from the deleterious effects of pro-inflammatory cytokines in the circulation. 
Apparently the effect of steroids on systemic and local cytokine concentrations are 
limited, as these concentrations were not significantly different between healthy and 
steroid rats. These findings are consistent with our data in patients with PCP, which 
showed that cytokine concentrations did not differ between steroid-treated and non-
steroid-treated patients [19,20]. 
The ex-vivo production however was profoundly influenced by corticosteroids administe-
red in vivo. LPS-stimulated pro-inflammatory cytokine production by alveolar cells in 
both PCP rats and steroid rats was not immediately suppressed, since it took 6 weeks 
before complete suppression was reached. These findings refute the suggestion of Huang 
et al that the beneficial effect of steroids on the clinical course of PCP is due to immedia-
te suppression of the pro-inflammatory cytokine production by alveolar cells [31]. 
Although ex-vivo cytokine production in whole blood cultures was also influenced by 
corticosteroids, the time course was different; in these cultures the cytokine production 
was immediately and profoundly suppressed. No production could be elicited at week 2, 
while a slight recovery was seen at week 4 and 6. This pattern was similar in PCP and 
steroid rats, suggesting a profound influence of steroids on the systemic cytokine res-
ponse. 
The differential effect of steroids on cytokine production in alveolar cells and blood is in 
agreement with the findings in patients with PCP. In steroid-treated HIV-seropositive pa-
tients with PCP, production of immunoreactive IL-6 and TNF in whole blood cultures 
was suppressed while the production in alveolar cells was not affected [20]. It also 
accords with the in vitro findings of Strieter et al, who showed that the effects of steroids 
on TNF production was more pronounced in peripheral blood monocytes than in alveolar 
macrophages [32]. In PCP in rats, the relative '"In-IgG uptake in the lung (L/M ratio) 
seems to be a better parameter of inflammation than the relative body weight, as it 
discriminates better between steroid-treated rats with and without PCP and hardly differs 
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between healthy and uninfected steroid rats. 
Although concentrations of IL-6 and IL-Iß were elevated in week 4 and 6, when there 
was established PCP, they did not correlate with the other inflammatory parameters, L/B 
and '"In-IgG L/M ratios. This was similar to our findings in patients, showing no 
correlation between cytokine concentrations and clinical seventy of the disease [19,20]. 
Despite some differences, the steroid induced PCP in the rat is a good model for human 
steroid-induced PCP and suitable to study the effect of cytokine modulation on the course 
of PCP. 
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ABSTRACT 
Concentrations and ex-vivo production of interleukin-lß (IL-Iß), tumor necrosis factor α 
(TNF), interleukin 6 (IL-6), interleukin 1 receptor antagonist (IL-IRA) and TNF soluble 
receptors were followed in broncho-alveolar lavage (BAL) fluid and blood in 10 HIV 
seronegative patients with Pneumocystis carinii pneumonia (PCP) and compared with 
values found in healthy volunteers. 
During the acute phase of PCP, TNF but not IL-6 or IL-lß was detectable in BAL fluid. 
At that time, plasma concentrations of the pro-inflammatory cytokines were low, while 
plasma concentrations of the anti-inflammatory cytokines were high. The ex-vivo 
production capacity of pro-inflammatory cytokines was suppressed in the acute phase, in 
the blood as well as at the site of infection. During convalescence the production capacity 
of the blood cells normalized. IL-1RA production capacity of the alveolar cells was also 
suppressed in the acute phase, but preserved in blood cells. 
INTRODUCTION 
Pneumocystis carinii is an intriguing pathogen, mainly causing pulmonary infections in 
immunocompromised hosts. Allthough deficient cellular immunity is considered a major 
predisposing factor for the development of Pneumocystis carinii pneumonia (PCP) the 
underlying mechanisms are still unclear. Clinical and experimental data suggest that 
CD4+ T-lymphocytes are critical in protection against PCP [1-3]. However, CD4+ 
lymphocytes are unlikely to function directly as effector cells in killing the organisms. 
Which cells act as effector cells is not clear, although macrophages have been shown to 
interact with the organisms [4-5]. Cytokines, the intercellular messengers, mainly derived 
from macrophages or T-helper lymphocyte subsets are involved in many inflammatory 
processes, are likely to be involved in the host defense against Pneumocystis carinii 
(P.carinii), but their exact role in PCP is not yet clear. 
In-vitro studies showed that P.carinii possesses binding sites for tumor necrosis factor-α 
(TNF-a) and that this cytokine was capable of killing P.carinii [6-8]. 
In mice TNF-a and interleukin-lß (IL-lß) are critical in the clearance of Pneumocystis, 
and interleukin-6 (IL-6) regulates pulmonary inflammation and antibody response during 
resolution of PCP [9-11]. In addition, several authors have reported the ability of 
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Pneumocystis to stimulate in-vivo and in-vitro production of TNF-a by alveolar macrop-
hages [12-17]. 
Thus, like in many bacterial and protozoal infections, IL-lß, IL-6, and TNF-a seem to 
play a role in the pathogenesis of PCP. 
We therefore studied the profile of these cytokines and their inhibitors in blood as well as 
at the site of infection in patients with PCP. Although at present most PCP episodes are 
seen in patients with HIV infection, it still is an important opportunistic infection in other 
immunocompromised patients, notably organ transplant patients and patients with 
lymphatic malignancies. 
A series of PCP in such HIV-seronegative patients, mainly renal transplant recipients, 
recently diagnosed at our hospital enabled us to follow cytokine concentrations and 
production capacity in bronchoalveolar lavage (BAL) fluid and in the blood. 
MATERIAL AND METHODS 
Patients 
All HIV-seronegative adult patients with PCP, diagnosed by BAL, between October 1992 
and March 1993 were included in the study. PCP diagnosis was based on demonstration 
of P.carinii organisms on Churukian-Schenk ammoniacal-silver stained and Giemsa 
stained BAL specimens [18]. 
At the time of BAL, blood samples of all patients were taken for measurement of 
circulating and ex-vivo produced cytokines and inhibitors; an other sample was obtained 
after full recovery. Nine patients were non smoking. All patients were proven seronega-
tive for HIV. None of the patients received non-steroidal anti-inflammatory drugs or 
pentoxyfyllin. 
The study was approved by the Hospital Ethical Committee and informed consent was 
obtained from all patients and healthy controls. 
Controls 
Eight non-smoking subjects, who volunteered to undergo BAL were used as controls. 
They were all in good health and none had risk factors for HIV infection. HIV testing 
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was not done for ethical reasons. None of them used medication or had evidence of lung 
disease or a history of recent respiratory tract infection. Prior to the BAL, a blood sample 
was taken for measurement of cytokines and white bloodcell count. 
Broncho-alveolar lavage 
After topical lidocaine anaesthesia of the oropharynx and bronchial tree, a flexible 
fiberoptic bronchoscope was introduced into the bronchial tree and, after inspection, 
wedged in a subsegmented bronchus serving the area of greatest radiologic abnormality. 
In the controls the lavage was done in the right middle lobe. BAL was performed by 
injecting and aspirating 6-8 aliquots of 20 ml sterile saline. The BAL fluid was collected 
via a closed system in a polypropylene flask. In patients most of the BAL fluid was used 
for diagnosis, the remaining fluid (in general 10-20 ml) for cytokine assessment. 
Processing BAL fluid 
Immediately following BAL, the flask was put on ice and transported to the laboratory. 
Thirty μ\ was taken for cell count and cell viability was assessed by trypan blue dye 
exclusion. The remaining fluid was centrifuged at 500g for 15 minutes. The supernatant 
was removed and 1% bovine serum albumin (BSA Sigma, St Louis, USA) was added. 
Then the fluid was filter sterilized, aliquoted and frozen at -80°C until assay. 
The pellet was resuspended in Dulbecco's modified Eagle's medium at a concentration of 
0.5 Χ 106 viable macrophages per ml; 100 μΐ was taken for preparing cytocentrifuged 
Giemsa stained preparations and half of the remaining fluid was then incubated in 4 ml 
closed polystyrene tubes (Greiner, Alphen aan de Rijn, Holland) without any addition 
(unstimulated culture) and the other half was incubated with Hpopolysaccharide (LPS, E 
Coli serotype 055;B5, Sigma) at a final concentration of 10 μg/ml. All incubations were 
done at 37° С for 24 hours. Following incubation the tubes are centrifuged at 1200g for 10 
minutes and the supernatant and cell pellets separately frozen at -80°C until cytokine 
analysis. 
Processing whole blood 
Venous blood was drawn from patients and volunteers for cytokine assessment in whole 
blood as described before [19]. In short, venous blood was collected aseptically into three 
5-ml-draw sterile vacuum tubes, containing lyophilized 7.2 mg EDTA and 250 μ\ 
aprotinin (Trasylol 2500 KIU, Bayer, Leverkussen, Germany;final concentration 625 
Cytokines in HIV-negative patients with PCP 4 3 
KIE/ml). 
One tube was immediately centrifugea at 1250g for 10 minutes, then plasma was 
transferred to a polypropylene tube (Eppendorf, Sarstedt, Nümbrecht, Germany) and 
centrifuged at 15000g for 1 minute in order to remove the platelets. This platelet-poor 
plasma was pipetted into another sterile polypropylene tube and frozen at minus -80 °C 
until cytokine analysis. 
In one of the two remaining tubes 50 μΐ LPS was added (final concentration 10 μg/ml) to 
stimulate cytokine production. This tube and the third tube were then incubated at 37 °C 
for 24 hours. After incubation the tubes were centrifuged and the plasma frozen at -80°C 
as described above. 
Cytokine assays 
Plasma and BAL samples were analyzed by means of specific radioimmunoassays for II-
lß , IL-1 receptor antagonist (IL-1RA) and TNF-a [20-21]. An Enzyme Linked Binding 
assay (ELIBA, Hoffman la Roche, Basel, Switserland) was used for soluble receptors of 
TNF-a (sTNF-R;P55, P75), and a bioassay (B9 hybridoma cell-line) for IL-6. 
The detection limits of the various assays were: IL-1 ß, 20 pg/ml; IL-1RA, 800 pg/ml; 
TNF, 20 pg/ml; sTNF-R:P55, 80 pg/ml, P75, 300 pg/ml; and IL-6, 20 U/ml. 
Since sTNF-R levels are reported to correlate with serum creatinine levels and with the 
glomerular filtration rate, a corrected value for sTNF-R concentration was calculated as 
follows : (actual sTNF-R concentration) χ ( creatinine clearance) χ 1/100 [22] 
Statistical analysis 
Values are reported as medians and range. Differences between medians were analyzed 
using the Wilcoxon signed-rank test for paired and unpaired samples. Ρ < 0.05 was 
considered significant. The one-way analysis of variance (ANOVA) was used to assess 
differences in the observed cytokine patterns between patients with and patients without 
concomitant infections. 
RESULTS 
Clinical characteristics of patients and controls 
All 10 patients (median age: 45 yearsjrange 29-69, 4 males, 6 females) had fever, dry 
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cough and/or dyspnoea. Nine patient had interstitial or alveolar infiltrates on the chest X 
ray, in one patient (number 4) the chest X ray was normal. 
ТаЫе 1. Cell differential (median and range) in BAL and peripheral blood 
Heallhy control subjects 
Health) control subjects 
PCP patients 
Granulocytes (%) 
2 
(1 5) 
7 
(2 45) 
BAL 
Lymphocytes (%) 
3 
(1 8) 
7 
(1-25) 
Macrophages 
95 
(92-99) 
75 
(45 97) 
(%) Granulocytes (%) 
57 
(18 65) 
82 
(4 99) 
Peripheral blood 
Lymphocytes (%) 
35 
(25 61) 
10 
(1-77) 
Monocytes (%) 
4 
(3-6) 
4 
(0 16) 
Of the patients 8 were renal transplant recipients with a median interval between 
transplantation and PCP of 3 months (range 2-30). One patient developed PCP while 
using prednisone for an undetermined auto-immune disease and one patient was treated 
with chemotherapy (including prednisone) for a non-Hodgkin's lymphoma. None of the 
patients used PCP chemoprophylaxis. The clinical and laboratory characteristics are 
summarized in Tables 1 and 2. The median age of the 8 healthy volunteers, 2 males and 
6 females, was 24 years (range 20-25). 
Table 2 Clinical characteristics of patients with PCP 
Patient number 
Underlying condition 
Duration of symptoms 
(weeks) 
Concomitant infections 
/>ao, (kPa) 
On respirator 
Bod> temperature ( C) 
at lime of hrst sample 
Prednisone dose (mg) 
at time of BAL 
al recovery or before death 
Other immuno 
suppressive drugs 
Oulcome 
Cure
v
de,uh 
at week 
1 
Renal 
TX 
4 
PTB 
5 0 
Ves 
38 5 
80 
20 
AZA 
Cure 
5 
2 
Renal 
TX 
3 
Sraph\locouur 
aureus 
6 5 
Yes 
37 8 
15 
10 
CsA 
Cure 
7 
sepsis 
3 
NHL 
< 1 
-
10 2 
No 
38 3 
0 
0 
-
Cure 
2 
4 
Renal 
I X 
< 1 
8 3 
No 
37 8 
80 
10 
AZA 
Cure 
2 
5 
Renal 
TX 
< 1 
СМ 
6 0 
Yes 
39 5 
40 
50 
CsA 
Death 
3 
6 
Renal 
TX 
3 
8 5 
No 
39 2 
80 
20 
CsA 
Cure 
1 
7 
Renal 
TX 
1 
-
8 5 
No 
39 0 
80 
20 
CsA 
AZA 
Cure 
2 
8 
Renal 
TX 
2 
-
9 4 
No 
4 0 4 
80 
10 
CsA 
AZA 
Cure 
1 
9 
Ailto-inimune 
disease 
6 
СМ 
6 9 
Yes 
39 6 
80 
100 
Death 
2 
10 
Renal 
TX 
1 
-
8 0 
No 
380 
80 
25 
CsA 
AZA 
Death 
3 
TX Transplantation, NHL, non-Hodgkin lymphoma, PTB, pulmonary tuberculosis, CM V. Cytomegalovirus early antigen delected in BAL 
fluid and therapy with gancyclovir, />ао2, arterial oxygen pressure, AZA, azathiopnne, CsA, cyclosporin A 
Cytokines in BAL and blood 
In BAL fluid of only one of the 10 PCP patients a measurable concentration of IL-6 (446 
U/ml) was present (Fig. la). TNF-a concentrations in the BAL fluid were high (6.1 
ng/ml) in one patient (number 7), detectable (0.1-0.6 ng/ml) in 5 patients and below the 
detection limit in 4 patients. IL-lß concentrations were detectable in 3 patients (0.16-0.24 
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\croncgaiive patients wiih PCP during Ihc acule phase and in 
геіллегу (lor plasma only) Ban, - range. 
ng/ml) and below the detection limit 
in 7. IL-IRA concentration in the 
BAL fluid of the PCP patients was 
2.1 (0.4-9.9) ng/ml (Fig. la). In 4 of 
the 10 patients, IL-1RA concentration 
in BAL fluid was above the upper 
normal limit of healthy volunteers (2: 
95% percentiles). The sTNF-R's 
could not be detected in BAL fluid, 
except in one (number 10), where 
values just above the detection limit 
were found (p55:1.2 ng/ml, p75:1.3 
ng/ml). 
IL-IRA in BAL fluid of healthy 
volunteers was 0.75 ( < 0.4-6.6) 
ng/ml, which was significantly lower 
than in patients (p=0.03, fig. la.). 
The concentrations of IL-6, TNF-a, 
IL-Iß and sTNF-R's in the BAL fluid 
of volunteers were below the detec-
tion limit. 
In the patients, the plasma con-
centrations of the pro-inflammatory 
cytokines, IL-6, TNF-a, IL-lß were 
low in the acute phase as well as at 
recovery (Fig. la). In contrast, the 
plasma concentration of the cytokine 
inhibitors were elevated in the acute 
phase. For IL-IRA we found 2.4 
(<0.8-10.3) ng/ml, for sTNF-R-p55 
10.8 (6.6-17.7) ng/ml and for sTNF-
R-p75 23 (14-36) ng/ml (Fig. lb). 
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Figure 2. Unstimulated and LPS-stlmuldted ex-vivo production of cytokines, (IL-6 and TNF, IL-I and IL-1RA) by alveolar cells and in whole-
blood cultures from volunteers and HIV-seronegalive patients with PCP in the acute phase and at recovery -, Median. · . patients without 
concomitant infections, O, patients with concomitant infections 
At recovery, while using low maintenance dose (10-20 mg) prednisone, the concentration 
of these inhibitors decreased in the patients, but remained significantly higher than in 
healthy volunteers (p<0.04). Even after correction for renal function, sTNF-R con­
centrations remained significantly higher compared to values of healthy volunteers, both 
in the acute phase, p55 :3.5 (1.5-7.4), p75:9.1 (3.7-19.5) ng/ml and in recovery, p55 2.7 
(0.8-8.7), p75 3.9 (2.6-15.2) ng/ml. Corrected for renal function, p75 concentration was 
higher in the acute phase (p=0.04) than in recovery, while for p55 concentration the dif­
ference in the acute phase and in recovery did not reach statistical difference. 
Cytokine concentrations in blood and BAL were not correlated with severity of infection. 
Ex-vivo production of cytokines by alveolar cells ami bloodcells 
In 6 patients (patients 1,2,5,7,8 and 10) adequate BAL material was obtained for 
assessment of ex-vivo production by alveolar cells. 
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Figure 2. Continued 
The LPS-stimulated ex-vivo production of the pro-inflammatory cytokines by the alveolar 
cells was suppressed in the acute phase of PCP (Fig.2 A and B). 
We also found a significant suppression of the unstimulated and LPS-stimulated ex-vivo 
production of IL-1RA by alveolar cells, compared to the production in healthy volunteers 
(p< 0.005, Fig.2B). BAL was not repeated during follow-up. 
The same pattern as with the alveolar cells was seen for the ex-vivo production of the 
pro-inflammatory cytokines in the whole blood cultures, i.e. suppression of the LPS-
stimulated ex-vivo production in the acute phase of PCP. At recovery the ex-vivo 
production returned to the values of the volunteers. In contrast, the ex-vivo production of 
IL-IRA did not appear to be affected by disease. After correction for circulating concen­
trations present in the cultured blood, both unstimulated and LPS-stimulated IL-IRA 
production was virtually identical in the acute phase and at recovery and similar to the 
production in volunteers (Fig.2B). 
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The ex-vivo production of sTNF-R was not measured since previous experiments 
demonstrated that TNF receptors were hardly released during LPS-stimulation in the 
alveolar cell and whole blood culture system (data not shown). 
In two patients with PCP, who were investigated recently, blood was drawn just before 
and 24 hours after the start of high dose (80 mg) prednisone; in both samples the pro-
inflammatory cytokine production was strongly suppressed (240 pg/ml and 260 pg/ml for 
IL-lß, 300 pg/ml and 580 pg/ml for TNF-a before the high dose prednisone versus 100 
pg/ml and 320 pg/ml for IL-lß, 220 pg/ml and 320 pg/ml for TNF-a after the high 
dose). 
ANOVA failed to detect differences in cytokine patterns between patients with and 
patients without concomitant infections ( for all cytokines Ρ > 0.13) 
DISCUSSION 
In this study, we followed in 10 HIV seronegative immunocompromised patients with 
PCP, circulating and ex-vivo production of cytokines in whole blood cultures during the 
course of infection and measured in the acute phase cytokine concentrations and ex-vivo 
production at the site of infection (BAL fluid and alveolar cells). 
Although in-vitro and animal studies suggest an important role of the pro-inflammatory 
cytokines in the pathogenesis of PCP early in the course of the infection, we found low 
concentrations of these cytokines in the blood as well as at the site of infection (i.e. in the 
BAL fluid) [9-11]. One explanation could be that at first examination of the patient, the 
infection has passed its initial acute stage, as most patients had symptoms for at least a 
couple of days. 
We could not detect a relationship between body temperature and plasma concentrations 
of the pyrogenic cytokines TNF-a, IL-lß and IL-6. Thus, it remains unclear how the 
febrile response during PCP is mediated . It is remarkable that even IL-6, a pyrogenic 
cytokine that reaches high circulating concentrations under many clinical conditions of 
systemic inflammation was not detectable. 
The high concentrations of the anti-inflammatory mediators IL-1RA and sTNF-R-p75 
(actual concentration as well as the concentration corrected for renal function) in the 
blood and IL-IRA in BAL fluid in the acute phase of the PCP suggest that counterregula-
tion of pro-inflammatory cytokines occurs in PCP. During convalescence, IL-IRA and 
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sTNF-R-p75 decrease, but remain above the levels seen in volunteers. What causes the 
high concentration of IL-IRA and P75 in these 'healthy' immunosuppressed patients 
needs further study. 
In our patients the LPS-stimulated ex-vivo production of the pro-inflammatory cytokines 
in blood cells was suppressed in the acute phase and improved during convalescence, 
while the production capacity of the anti-inflammatory cytokine IL-1RA was preserved. 
Previously we have observed a similar pattern in patients with severe meningococcal 
infection and in patients with typhoid fever [23-24]. Other investigators also reported 
suppression of pro-inflammatory cytokine after endotoxin infusion and during other acute 
disease states [25-26]. 
We hypothesize that during an acute infection, blood cells switch from a balanced pro-
inflammatory and anti-inflammatory repertoire (such as seen in healthy volunteers) to an 
anti-inflammatory repertoire. During the recovery phase the cells gradually regain the 
balanced status. The downregulation of pro-inflammatory cytokine production of cells in 
the circulation would not necessarily imply a similar downregulation at the level of the 
tissues and at the site of infection. However, in this study we find such downregulation of 
pro-inflammatory cytokines also at the level of the alveolar macrophages, pointing to a 
more generalized phenomenon. 
An intriguing finding is the disparity found between IL-IRA production by blood cells 
and alveolar cells. In volunteers, unstimulated alveolar cells readily produced IL-IRA, 
while unstimulated blood cells did not produce detectable amounts of this cytokine 
inhibitor. These findings are in agreement with observations of Moore et al, who found 
that alveolar macrophages express steady-state levels of IL-IRA mRNA under unstimu-
lated culture conditions, while peripheral blood cells did so only in response to LPS or 
adherent IgG [27-28]. In addition, we found differential regulation of IL-1RA between 
blood and alveolar cells in the acute phase of PCP: here IL-IRA ex-vivo production could 
be stimulated in the blood, but not in alveolar cells. Whether this downregulation of the 
anti-inflammatory response has consequences e.g. in terms of pulmonary damage needs 
further study. 
It is of interest that despite the low TNF-a production capacity of the alveolar cells, 
TNF-a is present in the BAL fluid of 60% of the patients with PCP. The cellular source 
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of this TNF-α is currently unclear but unlikely to be derived from alveolar macrophages, 
since these cells are refractory in terms of TNF-α production. 
What accounts for the downregulation of pro-inflammatory cytokine production with 
relatively preserved IL-IRA production in the course of an infection needs further 
research. IL-4, a T-lymphocyte derived cytokine known to block the production of IL-Iß, 
IL-6 and TNF-α by monocytes, is a potent stimulus for IL-1RA production [29-30]. It 
could therefore be involved in the switch. Likewise, the cytokines IL-10 or Tumor 
Growth Factor-ß could be involved [31-32]. 
An important question is what role immunosuppression and the concomitant infections 
play in our study. Several investigators indicate that glucocorticosteroids and cyclosporine 
A decrease pro-inflammatory cytokine production [33-35]. With regard to IL-1RA 
production, Santos et al. have reported a minimal influence of hydrocortisone on 
endotoxin stimulated IL-IRA production in volunteers [36]. In our study however, the 
pattern of cytokine production did not appear to be influenced by prednisone dose 
(ranging from 0-80mg in the acute phase and from 0-20mg in convalescence) and 
cyclosporin A treatment. The concomitant infections occurring in our patients did seem to 
influence cytokine patterns in the same direction as PCP, since the cytokine patterns of 
the 6 patients without concomitant infections were not different from the others. 
Although it is reasonable to presume that the immunosuppressive drugs and the concomi-
tant infections in these patients interfered with the magnitude of the cytokine production, 
the observed cytokine patterns do not seem to be greatly influenced by either these drugs 
or the concomitant infections. 
In conclusion, we found elevated TNF-α concentrations in BAL in acute PCP and 
elevated plasma levels of the anti-inflammatory cytokine IL-1RA and the soluble TNF 
receptors in the acute phase of a PCP in 10 HIV seronegative patients, with at the same 
time a suppressed production of pro-inflammatory cytokines, in the blood as well as at the 
site of infection. During convalescence the blood cells return to a balanced pro-inflam­
matory status. 
IL-1RA production in acute PCP was downregulated in alveolar cells and preserved in 
blood cells. 
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ABSTRACT 
Objective: To investigate cytokine profiles in Pneumocystis carinii pneumonia (PCP) in 
HIV-seropositive (HIVpos) patients and to correlate cytokine levels with disease activity. 
Design: Prospective multicenter clinical study. 
Methods: Concentrations of interleukin-lß (IL-lß), tumor necrosis-α (TNF-a), interleu-
kin-6 (IL-6), interleukin-1-receptor antagonist (IL-1RA) and TNF soluble receptors were 
measured in broncho-alveolar lavage fluid (BAL) and blood of 23 HIVpos patients with 
PCP and compared with the concentrations in healthy HIV-seronegative controls and 
asymptomatic HIVpos persons. We also examined ex-vivo production by alveolar cells 
and in whole blood cultures. 
Results: IL-1 was increased in BAL of HIVpos patients with PCP (117, range <20-
1010pg/ml) compared to healthy controls (<20pg/ml, p= 0.0001). In plasma of the 
HIVpos patients higher concentrations of IL-IRA were found during acute PCP compared 
to levels after recovery (1.3, range <0.8-17.0 versus <0.8, range <0.8-2.0ng/ml, 
ρ=0.01). Ex-vivo production of pro-inflammatory cytokines was suppressed in whole 
blood cultures during PCP, whereas IL-IRA production by alveolar cells as well as in 
whole blood cultures was increased. Corticosteroids did not affect cytokine concentrations 
in BAL or blood, nor did they suppress the production in alveolar cells. In whole blood 
cultures however, LPS-stimulated production was significantly suppressed for IL-1 (0.3, 
range 0.1-7.4 versus 5.7, range 0.7-30.3ng/mI, p= 0.009) and for IL-6 (0.18 range 0.03-
2.96 versus 2.06, range 0.16-4.95ng/ml, p=0.01). Correlations between inflammatory 
mediators and disease activity were not found. 
Conclusion: In PCP pro-inflammatory cytokines are predominant in BAL, whereas anti­
inflammatory mediators are more prominent in blood. 
INTRODUCTION 
Pneumocystis carinii pneumonia (PCP) is the most frequently occurring severe opportu­
nistic infection in patients infected with the human immmunodeficiency virus (HIV). 
Clinical and experimental data suggest that CD4+ T-lymphocytes are important for 
protection against PCP, although not directly as effector cells [1-3]. Macrophages have 
been shown to directly interact with the Pneumocystis carinii (P.carinii) [4-7]. Cytokines 
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are likely to be involved as soluble mediators in the host defense against P.carinii but 
their exact role remains to be established. 
P.carinii is able to stimulate in-vivo and in-vitro production of tumor necrosis factor-α 
(TNF-a) by alveolar macrophages [8-13]. In-vitro studies suggest that P.carinii possesses 
binding sites for TNF-a and that this cytokine is capable of killing P.carinii [14-15]. In 
mice, TNF-a and interleukin-lß (IL-Iß) are important for the clearance of P.carinii, 
while interleukin-6 (IL-6) regulates pulmonary inflammation and antibody response during 
resolution [16-18]. Thus, similar to a variety of other infections IL-lß, IL-6, and TNF-a 
seem to play a role in the pathogenesis of and protection against PCP. 
To investigate the role of these pro-inflammatory cytokines in patients with PCP, we 
studied the profiles of IL-lß, TNF-α, IL-6 and their inhibitors, IL-1 receptor antagonist 
(IL-1RA) and the soluble TNF receptors (sTNF-R) in blood as well as in broncho-
alveolar lavage (BAL) fluid. 
MATERIAL AND METHODS 
Patients 
Twenty three adult HIV-positive (HIVpos) patients with PCP, who underwent BAL 
according to a standardized protocol (see below) at the 4 participating centres were 
included in the study between October 1993 and November 1994. The diagnosis PCP was 
based on demonstration of P.carinii organisms on Silver and/or Giemsa stained BAL 
specimens [19]. 
Blood samples for measurements of circulating and ex-vivo produced cytokines and 
inhibitors were taken at the time of the BAL and after full recovery. 
Respiration rate and arterial oxygen pressure (P02) on admission were used as parameters 
for severity of infection. 
Controls 
Eight healthy non-smoking subjects, who volunteered to undergo BAL were used as 
controls [20]. None of them used medication or had evidence of lung disease or a history 
of recent respiratory tract infection. Prior to the BAL, a blood sample was taken for 
measurement of cytokines and white blood cell count (WBC). 
Blood was obtained for cytokine measurements from twenty-five asymptomatic ambulant 
Cytokines in HIV-positive patients with PCP 57 
HIVpos individuals with varying CD4 counts who visited the HIV-clinic of the University 
Hospital Nijmegen. They were the asymptomatic HIVpos control group. 
Broncho-alveolar lavage 
After topical lidocaine anaesthesia of the oropharynx and bronchial tree, a flexible 
fiberoptic bronchoscope was introduced into the bronchial tree and, after inspection, 
wedged in a subsegmentai bronchus serving the area of greatest radiologic abnormality. In 
the controls the lavage was done in the right middle lobe. BAL was performed by 
injecting and aspirating 6-8 aliquots of 20 ml sterile saline. In patients most of the BAL 
fluid was used for diagnosis, the remaining fluid (in general 10-20 ml) for cytokine 
assessment. 
Processing BAL-fluid 
Immediately following BAL, 30 μ\ was taken for cell count and cell viability was assessed 
by trypan blue dye exclusion. The remaining fluid was centrifuged at 500g for 15 
minutes. The supernatant was removed and one percent bovine serum albumin (Sigma, St 
Louis, USA) was added. Then the fluid was filter sterilized, aliquoted and frozen at -80°C 
until assay. 
The pellet was resuspended in Dulbecco's modified Eagle's medium at a concentration of 
0.5 X 10* viable macrophages per ml; 100 μ\ was taken for preparing cytocentrifuged 
Giemsa stained preparations and half of the remaining fluid was incubated in 4 ml closed 
polystyrene tubes (Greiner, Alphen, The Netherlands) without any addition (unstimulated 
culture) while the other half was incubated with lipopolysaccharide (LPS, E Coli serotype 
055;B5, Sigma) at a final concentration of 10 /tg/ml. All incubations were done at 37° С 
for 24 hours. Following incubation the tubes were centrifuged at 1200g for 10 minutes 
and the supernatant and cell pellets separately frozen at -80°C until cytokine analysis. 
Processing whole blood 
Venous blood was drawn from patients and controls for cytokine assessment in whole 
blood as described before [21]. Briefly, venous blood was collected aseptically into three 
5-ml-draw sterile vacuum tubes, containing lyophilized 7.2 mg EDTA and 250 μ\ 
aprotinin (Trasylol 2500 KIU, Bayer, Leverkusen, Germany; final concentration 625 
KIE/ml). 
One tube was immediately centrifuged at 1250g for 10 minutes. Plasma was transferred to 
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a polypropylene tube (Eppendorf, Sarstedt, Niimbrecht, Germany) and centrifuged at 
15000g for 1 minute to remove platelets. Platelet-poor plasma was pipetted into another 
sterile polypropylene tube and frozen at minus -80 °C until cytokine analysis. 
In one of the two remaining tubes 50 μ\ LPS was added (final concentration 10 pg/ml) to 
stimulate cytokine production. This tube and the third tube were then incubated at 37 °C 
for 24 hours. After incubation the tubes were centrifuged and the plasma frozen at -80°C 
as described above. 
Cytokine assays 
Plasma and BAL samples were analyzed by specific radioimmunoassays for II-Iß , IL-1 
receptor antagonist (IL-1RA) and TNF-a [22,23]. An Enzyme Linked Binding assay 
(Hoffman-la Roche, Basel, Switserland) was used for soluble receptors of TNF (sTNF-
R;P55, P75), and an ELISA as described before for IL-6 (Inotherapy, Besançon, France) 
[24]. 
The detection limits of the various assays were: IL-lß, 20 pg/ml; IL-1RA, 800 pg/ml; 
TNF-a, 20 pg/ml; sTNF-R:P55, 80 pg/ml, P75, 300 pg/ml; and IL-6, 20pg/ml. 
Statistical analysis 
Values are reported as medians and ranges. Differences between groups were analyzed 
with the Wilcoxon rank sum test. For paired samples the signed rank test was used. 
Correlations between variables were estimated with Spearman's rank correlation coeffi-
cient. P-values of 0.05 or less were considered significant. 
The study was approved by the Hospital Ethical Committee and informed consent was 
obtained from all patients and healthy controls. 
RESULTS 
Clinical characteristics 
Clinical characteristics of patients and controls are shown in table 1. PCP prophylaxis 
was only used by 4 patients (17%), all of them used monthly Pentamidin. Mean duration 
of symptoms was 5 (±5) weeks. Mean arterial oxygen pressure was 8.6 (± 1.5) kilo 
Pascal. Eight (35%) patients had Cytomegalovirus-early-antigen in BAL fluid. Two (9%) 
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patients needed a respirator and 2 (9%) died. Four of the 23 HIVpos patients with PCP 
(17%) had concomitant infections (two had cerebral toxoplasmosis, one cryptococcal 
pneumonia and one salmonella septicaemia). 
Table 1. Clinical characteristics of patients and controls 
Total number 
male (%) 
age in years (SEM) 
smokers (%) 
CD4 cells/mm3 (SEM) 
corticosteroids (%) 
body temperature (SEM) 
WBC χ 10.9/L (SEM) 
% neutrophils (SEM) 
% monocytes (SEM) 
% neutrophils in BAL (SEM) 
% macrophages in BAL 
(SEM) 
HIVpos 
PCP 
23 
23 (100) 
35.8 (6.0) 
9 (39) 
97 (133) 
8(35) 
38.4°C(1.0) 
5.6 (0.5) 
76(3) 
6(5) 
15 (2.7) 
68 (4.4) 
HIVpos 
asymptomatic 
25 
20 (80) 
37.4 (8.8) 
12 (48) 
207 (226) 
0 
<37.5°C 
4.2 (0.4) 
57 (2.2) 
8(1) 
ND 
ND 
healthy con­
trols 
8 
2(25) 
23.3 (1.6) 
0(0) 
ND 
0 
<37.5°C 
5.0 (0.5) 
57 (3.6) 
4(2) 
2 (0.6) 
95(1.1) 
Legends : HIVpos = HIV seropositive, PCP = Pneumocystis carinii pneumonia, SEM = 
standard error of the means, ND = not done, BAL= broncho-alveolar lavage fluid. 
Cytokine concentrations in BAL fluid and in plasma 
BAL - BAL was performed in the acute phase of PCP and in healthy controls. Concen­
trations of all three pro-inflammatory cytokines were generally higher in the acute phase 
of PCP compared to levels in healthy controls, but significance was only obtained for IL-
lß (p=0.0001, Fig.lA). Although concentrations of IL-1RA were high in 3 HIVpos 
patients (>10 ng/ml), the difference with healthy controls did not reach statistical 
significance (Fig. IB). Both types of soluble TNF-receptors were low in BAL fluid. 
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Fig 2 LPS-stimulated ex-vivo cytokine production in BAL (Fig2A) and blood (Fig 2B) in HIVpos patients with PCP 
during the acute phase (AC) and recovery (REC), in asymptomatic HIVpos subjects (AS) and in healthy controls (CO) 
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Plasma - With exception of IL-1RA (p=0.01), plasma concentrations of the pro-inflam-
matory cytokines and anti-inflammatory mediators did not differ between the acute and 
recovery phase in HIVpos patients with PCP (fig. ID). 
HIVpos patients with PCP had higher circulating concentrations of IL-lß (p=0.002, 
Fig.1С), IL-1RA and P75 (p=0.01, Fig.ID) than asymptomatic HIVpos patients. 
Compared to healthy controls, HIVpos patients with PCP had significantly higher 
concentrations of pro-inflammatory cytokines (p< 0.002, Fig. 1С) and of sTNF-receptors 
(p<0.0006, Fig.ID), whereas IL-1RA did not differ between the two groups. 
Ex-vivo production of cytokines 
Alveolar cells - During the acute phase of PCP, LPS-stimulated production of pro­
inflammatory cytokines by alveolar cells of HIVpos patients did not differ from the 
production of healthy controls (Fig.2A), whereas LPS-stimulated production of IL-1RA 
was significantly higher (p=0.01, Fig.2A). Similarly, unstimulated ex-vivo production 
showed higher production of IL-1RA in HIVpos patients with PCP, median 12.5, range 
1.6-95 ng/ml versus median 6.5, range 0.8-9.7 ng/ml in healthy controls, p<0.05. 
Whole blood cultures - LPS-stimulated production of IL-6 and TNF-a was suppressed in 
the acute phase of PCP, and restored during recovery (Fig.2B.). Although the same trend 
was seen for production of IL-lß, the difference was not significant. Production of IL-
1RA tended to be higher in the acute phase than during recovery, the difference was 
however not significant. Compared to asymptomatic HIVpos persons, pro-inflammatory 
cytokine production was slightly lower in the acute fase of PCP and higher during 
recovery. Compared to healthy controls, LPS-stimulated production of TNF-a in HIVpos 
patients in the acute phase of PCP was significantly suppressed (p=0.007, Fig.2B) and 
IL-1RA production capacity increased (p=0.01, Fig.2B). 
Unstimulated production of pro-inflammatory cytokines was higher in HIVpos persons as 
compared to HIVneg controls and not influenced by the presence of PCP. Median 
concentrations in all HIVpos persons were 110 pg IL-lß per ml (range <20-640 pg/ml) 
and 102 pg TNF-a per ml (range 60-282 pg/ml), while concentrations in healthy controls 
were <20 pg IL-lß per ml (range <20-280 pg/ml), and 80 pg TNF-a per ml (range 60-
120 pg/ml). 
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Table 2. Effect of corticosteroids on (anti-)inflammatory mediators. Plasma concentrations 
and LPS-stimulated production of (anti-)inflammatory mediators were measured in 2 
HIVpos patients with PCP before administration of 40 mg prednisone (C-) and 24 hours 
after the first dose (C+). 
Data show ng/ml. 
Plasma concentration LPS-stimulated ex-vivo production 
1 
| Patient A 
1 IL-lß 
IL-6 
TNF-a 
IL-IRA 
sTNF-R, p55 
sTNF-R, p75 
patient В 
IL-lß 
11-6 
TNF-a 
IL-IRA 
sTNF-R, p55 
sTNF-R, p75 
C-
0.12 
<0.02 
0.11 
1.0 
3.0 
7.5 
0.10 
0.01 
0.09 
1.2 
4.75 
11.5 
C+ 
0.11 
<0.02 
0.11 
<0.8 
2.5 
7.25 
0.13 
0.02 
0.10 
1.4 
3.5 
15.0 
C-
31.8 
3.36 
3.39 
25.3 
< detection 
limit 
< detection 
limit 
0.44 
0.16 
0.18 
4.6 
< detection 
limit 
< detection 
limit 
C+ 
0.80 
0.38 
1.20 
9.3 
< detection 
limit 
< detection 
limit 
0.12 
0.15 
0.13 
3.0 
< detection 
limit 
< detection 
limit | 
Effects of glucocorticosteroids and/or concomitant infections on cytokines in HIVpos 
patients with PCP 
Corticosteroids (40-60mg prednisone) were given in 8 patients at 2-24 hours before BAL. 
Concentrations of cytokines in BAL and plasma did not differ from the 15 patients who 
were not treated with corticosteroids. LPS-stimulated production in alveolar cells also did 
not differ significantly between these two groups (data not shown). However, LPS-
stimulated ex-vivo production in whole blood showed significantly reduced IL-lß (median 
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300, range 100-7400 pg/ml) and IL-6 (median 180, range 30-2960 pg/ml) production in 
corticosteroid-treated patients as compared to untreated patients (IL-lß mean 5700, range 
700-30300 pg/ml, p= 0.009 and IL-6 mean 2060, range 160-4950 ng/ml, p=0.01); 
there was no difference in TNF-α and IL-IRA synthesis. In 2 patients circulating concen­
trations of cytokines were not different before and within 24 hours after steroids ad­
ministration. However, profound effects were seen on whole blood cytokine production in 
one patient, while in the other patient the production was already reduced before the 
administration of corticosteroids (Table 2). 
Cytokine concentrations and production of the 4 HIVpos patients with PCP and another 
opportunistic infection (cerebral toxoplasmosis in two, cryptococcal pneumonia in one and 
salmonella septicaemia in one) were similar to those without concomitant infections. The 
same holds for the presence or absence of Cytomegalovirus in BAL fluid (data not 
shown). 
DISCUSSION 
HIVpos patients with PCP showed higher concentrations of the pro-inflammatory cytokine 
IL-lß in BAL fluid than healthy controls. In the circulation, higher concentrations of the 
anti-inflammatory cytokine IL-1RA were found than during recovery. 
Pro-inflammatory cytokines have previously been shown to be increased in BAL fluid of 
HIVneg patients with PCP [20]. TNF-α was significantly increased in BAL fluid of 
HIVneg renal transplant patients, while in this study IL-lß is high in BAL fluid of 
HIVpos patients. These differences may be related to different underlying immune defects 
or disease stages. Anti-inflammatory mediators in BAL fluid of HIVneg and HIVpos 
patients with PCP show low concentrations of s-TNF receptors, while IL-1RA is 
significantly increased in the HIVneg patients and marginally increased in HIVpos 
patients. These data do not corroborate findings by Millar et al. who reported increased 
production of TNF-α by alveolar macrophages in HIVpos patients with PCP [25]. 
Differences in cell populations (adherent cells versus unselected BAL cells in our study), 
incubation time (4 versus 24 hours) and assays (immunoassay versus RIA) might be 
responsible for these discrepancies. 
In the circulation concentrations of these anti-inflammatory mediators were higher in the 
acute phase of PCP than during recovery in both HIVneg and HIVpos patients. It is 
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tempting to hypothesize that the high concentration of anti-inflammatory mediators in the 
circulation ensures that the effect of the pro-inflammatory cytokines remains limited to the 
focus of infection. The host is subsequently protected against the deleterious systemic 
effects of pro-inflammatory cytokines, including damage to the endothelium, shock and 
mortality. At the site of infection, these cytokines are important as early response 
mediators regulating cellular function, activating the host response against P.carinii and 
dictating events leading to repair of tissue injury. Their presence in BAL in patients with 
PCP is in accordance with the findings in in-vitro and animal studies showing that TNF-or 
and IL-lß play a role in the acute phase of PCP [12,13,17,18]. 
For cytokine patterns in the lung, we had to compare HIVpos patients with healthy 
controls because a BAL procedure was not considered eligible during recovery or in 
asymptomatic HIVpos persons. For cytokines in the circulation, acute phase was compa-
red with recovery in the same patients to match for the presence of HIV infection. These 
data must be interpreted with some caution because of the use of different controls. 
Nevertheless our principle conclusion of divergence of local and systemic cytokine profile 
is supported by similar data in HIVneg patients with PCP [20] and a rat model [Peren-
boom et al, submitted]. 
Correlations between inflammatory mediators and disease activity were not found in our 
study (data not shown). This is in contrast to findings of Benfield et al. who showed a 
significant correlation between the chemotactic cytokine IL-8 and severity of infection, as 
determined by P02 and BAL neutrophilia [26,27]. TNF-a and IL-lß, which are able to 
induce IL-8, may have been present early in the disease process but may have disappea-
red at the first presentation of the patient. From other infectious diseases, e.g.meningo-
coccal sepsis, we have found that IL-8 remains much longer in the circulation than IL-lß 
and TNF-a [28]. The high circulating concentrations of pro-inflammatory cytokines in 
HIVpos patients with PCP should be interpreted against the background of cytokine 
abnormalities in HIV. We could confirm that HIV infection per se results in high plasma 
concentrations of pro-inflammatory cytokines and s-TNFR's, and also in increased 
unstimulated pro-inflammatory cytokine production [29-31]. PCP did not further increase 
these plasma concentrations and unstimulated production. Plasma IL-lß concentration in 
the acute phase of PCP in HIVpos patients was not significantly increased as compared to 
recovery, but was significantly higher than in asymptomatic HIVpos persons, which might 
be explained by the more severe HIV infection in the PCP patients; mean CD4 count 97 
versus 207 in the asymptomatic persons (Table 1). 
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In a recent study, Huang et al. found diminished LPS-stimulated production of IL-lß and 
TNF-a by alveolar cells of AIDS patients with PCP who received corticosteroids and 
suggested that the beneficial effect of steroids in PCP may be due to a local reduction of 
pro-inflammatory cytokine production [32]. In our study, however, production of pro-
inflammatory cytokines by alveolar cells in HIVpos patients with PCP, was not reduced, 
even in patients who received high dose corticosteroids 2-24 hours before BAL. It is 
therefore not likely that the beneficial effect is due to suppression of local production of 
pro-inflammatory cytokine, unless one assumes that increased pro-inflammatory cytokine 
production in severe PCP is counteracted by suppression of corticosteroids. Our data from 
steroid-induced PCP in a rat model do not support the latter hypothesis [Perenboom et al, 
submitted]. 
Both HIVneg patients and HIVpos patients with PCP treated with steroids, showed 
suppressed production of pro-inflammatory cytokines in whole blood cultures in the acute 
phase. In contrast, pro-inflammatory cytokine production was not suppressed in the 
HIVpos patients with PCP, who did not receive steroids. Production in the latter group 
did neither differ from that in recovery, nor from that in asymptomatic HIVpos indivi-
duals. The high dosages of corticosteroids were only given to patients with P02 < 8 kPa 
[33]. Thus, severe infection could also be responsible for suppression of pro-inflammatory 
cytokine production [28,34,35]. In 3 of 4 patients with PCP (2 HIVpos of the present 
series and 2 HIVneg [20]), blood was taken before and after high dose corticosteroids; in 
these patients we found that cytokine production was already suppressed before administ-
ration of steroids. Since all four patients had severe PCP with low P02, severe infection 
rather than corticosteroids seems to lead to downregulation of systemic pro-inflammatory 
cytokine production. 
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ABSTRACT 
We investigated the possible therapeutic role of TNF and a polyclonal murine anti-TNF-
antibody in experimental PCP, in which the growth of the micro organisms as well as the 
magnitude of the host response could be monitored. P.carinii load was measured in the 
P.carinii density score. The inflammatory response was quantified by means of the 
lung/body weight ratio and the lung/muscle ratio in ' " Indium biodistribution, both 
proven in an earlier study to correlate with other inflammation parameters. 
In experimental Pneumocystis carinii pneumonia, intratracheal TNF in the first weeks 
after infection in addition to suboptimal cotrimoxazole was not synergistic in eradication 
of Pneumocystis. Treatment with intratracheal anti-TNF in the 5th and 6th week after 
infection combined with standard dose cotrimoxazole did not reduce inflammation. 
INTRODUCTION 
Pneumocystis carinii pneumonia (PCP) is a common infectious complication in patients 
infected with the human immunodeficiency virus (HIV). 
Tumor necrosis factor-α (TNF-α) seems to play a role in host defense against PCP. 
Increased concentrations of TNF-a have been detected in broncho-alveolar lavage (BAL) 
fluid of patients with PCP [10]. In mice, TNF-a was found necessary early in the infecti­
on to clear P.carinii (PC) [8]. In-vitro experiments suggest that TNF-a could kill P.carinii 
directly [12]. Despite these arguments for a favourable role in PCP, TNF-α is also known 
to be deleterious in serious infections. Endothelial damage and fibrosis may ensue from 
its action and such effects could occur in PCP. 
Thus, TNF-α may be important in the beginning of infection to orchestrate microbicidal 
activity against P.carinii, whereas TNF-induced inflammation could result in respiratory 
failure and systemic symptoms at a later stage of disease. To test this hypothesis we 
investigated, in the rat, the effects of intratracheally administered TNF-α or a-TNF 
antibodies (a-TNF-abs) at different time points during PCP in combination with cotri­
moxazole. 
MATERIAL AND METHODS 
Four to six weeks old, female Spraque-Dawley rats, were immunosuppressed with weekly 
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subcutaneous injections of 25 mg hydrocortisone and 8% protein-restricted diet. PCP was 
induced by close cohabitation with P.carinii infected rats. Co-infections were excluded by 
regular microbiological screening. 
Two days before the animals were sacrificed, luIndium-IgG (luIn-IgG) was given intrave­
nously as described [11]. Uptake of '"In-IgG was measured in the right upper lung lobe 
and compared to normal calf muscle to calculate lung to muscle (L/M) ratios. PC density 
was assessed in Giemsa and silver stained impression smears and expressed in the loga­
rithmic PC density score [3]. 
Post mortem broncho-alveolar lavage (BAL) was performed. BAL fluid and blood were 
collected and incubated with and without lipopolysaccharide (LPS) for 24 hours, as 
described before [11]. Supernatant and cell pellets were frozen at -80°C until analysis. 
The left upper lung lobe was homogenized, centrifuged and the supernatant frozen until 
analysis. 
TNF-a was measured in plasma, BAL and lung homogenate samples by L929 cytotoxicity 
bio-assay (detection limit 20 pg/ml)[l,2]. Trimethoprim-sulfamethoxazole (Roche, The 
Netherlands) was administered by gavage in different dosages once daily during week 5 
and 6 after start of the immunosuppression. Recombinant-murine-TNF-a was donated by 
Dr.G.Adolf, Emst-Boehringer Institut, Vienna, Austria. Specific activity was 1.2xl07 
U/mg in LM cells; endotoxin concentration was <51 pg/ml. 
Polyclonal or-TNF-antibodies were raised in a rabbit by intradermal administration of 50 
μg recombinant-murine-TNF-α (rec-mTNF-α) in Freund's complete adjuvant and boosting 
with Freund's incomplete adjuvant. The rabbit antiserum was able to neutralize rat TNF-a 
in the L929 bio-assay. The amount of rec-mTNF-a that caused lysis of 50% of the L929 
cells was defined as one unit of rec-mTNF-α and corresponded to 70 pg/ml. The amount 
of rabbit antiserum neutralizing 1 unit rec-mTNF-α was defined as one neutralizing unit 
(NU). The rabbit antiserum thus tested, contained 3 χ 10* NU/ml. In-vivo, intraperitoneal 
administration of 1.2 χ IO6 NU α-TNF-abs in rats, was able to completely neutralize 
LPS-induced plasma TNF-a concentrations of 135-173 ng/ml. 
As control, a monoclonal rat-anti-mouse-TNF-antibody (Moabs), V1Q (a gift from 
Dr.P.H.Krammer, Heidelberg, FRG) showed no neutralizing activity in the L929 bio-
assay. 
TNF-a and α-TNF-abs were administered intratracheally under ether anaesthesia as des­
cribed [7]. In short, a modified spinal needle was inserted between the vocal folds, 200 /xl 
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Fig.l 
PC score and inflammatory parameters in ex­
perimental PCP in rats, treated with a 2 weeks 
course of cotrimoxazole. PC score = Pneumo-
• ' L/B ratio 
cystis carinii density score on Giemsa stained 
ШШ UU ratio 
impression smears of the lungs. L/B ratio = 
Lung to body weight ratio. L/M ratio = '"" 
0 mg 3 mg 30 mg 300 mg Indium biodistribution lung to muscle ratio. Each 
cotrimoxazole dose (per kg per day) 
column represents the mean and SEM of 5-7 rats. 
PC score, L/B ratio and L/M ratio were sig­
nificantly reduced in all cotrimoxazole treated rats 
as compared to the untreated rats (Mann-Whitney 
test, ρ < 0.05). 
solution was instilled, whereafter 2 ml air was injected with some force to increase 
dispersion of the solution in the lungs. 
Statistics - Data are given in means and standard error of the means (SEM). Differences 
between groups were analysed by the non-parametric Mann-Whitney test. 
The study was approved by the University Committee on Animal Experiments. 
RESULTS 
As shown in fig.l, treatment with both 300 and 30mg/kg cotrimoxazole eradicated all 
cysts and significantly lowered L/B and L/M ratios, while 3mg/kg significantly reduced 
the number of cysts. Combination of suboptimal cotrimoxazole (3mg/kg) with lOOng rec-
mTNF-a intratracheally once weekly during week 1-3 in the early phase of PCP did not 
change the number of PC cysts (fig.2a). 
Pilot experiments had shown that 300mg/kg cotrimoxazole increased signs of inflammati­
on, as indicated by increased L/B ratios after one week of treatment (data not shown). 
Addition of a-TNF-abs, 6xl04 NU, sufficient to neutralize at least 7500 pg/ml rat 
F¡g.2 
UU rallo 
TNF modulation in PCP 73 
PC iene* I 1 L/B rallo L/M » I lo 
rb 
:шо id 
Я І 
ál 
JG 
• 
τ 
_L -Œ 
II 
в 
» g Эгад, TNF Эшд, control ab ЭООшд ЭООшо, 0-TNF ЭООпд, c o n i n o 
PC score and inflammatory parameters in experimental PCP in rats, treated with either a 2 weeks course of 
cotrimoxazole 3 mg/kg per day in combination with intratracheal administration of TNF early in the 
infection (fig.2A) or with cotrimoxazole 300mg/kg per day and a-TNF-abs intratracheally late in the 
infection (fig.2B). Control rats were given an antibody without neutralizing activity (contr.ab). PC score 
= Pneumocystis carinii density score on Giemsa stained impression smears of the lungs. L/B ratio = Lung 
to body weight ratio. L/M ratio = '"Indium biodistribution lung to muscle ratio. Each column represents 
the mean and SEM of 3-5 rats. PC score, L/B ratio and L/M ratio did not differ between groups treated 
with the same dose cotrimoxazole with or without intratracheal TNF or a-TNF-abs (Mann-Whitney test). 
TNF-a, intratracheally twice weekly to 300mg/kg cotrimoxazole daily in week 5 and 6, 
did not affect L/B and L/M ratio as compared to cotrimoxazole with control Mabs 
(fig.2b). Bio-active TNF-a was measured in week 6, in BAL fluid, lung homogenates and 
plasma in rats treated with 300mg/kg cotrimoxazole monotherapy, 3mg/kg cotrimoxazole 
combined with intratracheal TNF-a or 300mg/kg cotrimoxazole and intratracheal TNF 
antiserum. In all groups there was no significant difference between TNF-a concentra­
tions (63-100 pg/ml) in BAL and lung homogenates, while TNF-a levels in plasma were 
undetectable. In all groups LPS-stinuilated TNF-a production by alveolar cells was 
>2000 pg/ml, while production in whole blood cultures was under the detection limits. 
DISCUSSION 
Protection by exogenous recombinant TNF-a has been demonstrated in-vitro and in-vivo 
in a number of infection models, even in pulmonary infection. Blanchard et al demon­
strated a protective effect of TNF-a in experimental Legionella Pneumophilia infection 
[5]. Beck et al reported benefit of intratracheal IFN-gamma in PCP in mice suggesting 
that part of this was due to priming macrophages for TNF-a release [4]. 
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Beneficial effects of a-TNF-abs in adjunct to antimicrobial therapy were reported in 
sepsis [14]. In humans with PCP, hypoxia often increases after initiation of therapy and 
corticosteroids are used to prevent the initial decline in oxygenation and improve progno­
sis [6]. Drug-induced death of P.carinii may enhance the inflammatory responses. This 
hypothesis is supported in this study by the slightly higher L/B ratio observed after one 
week of high dose cotrimoxazole treatment. 
However, intratracheal administration of TNF-α in the first weeks of PCP in combination 
with suboptimal cotrimoxazole doses neither resulted in a decline of P.carinii density 
score, nor in lower L/B and L/M ratios. 
The presence of bioactive TNF-α in BAL and lung homogenates after 2 weeks of cotri­
moxazole (in any regimen) suggests that TNF-α is indeed induced by killed PC, since no 
TNF-α could be detected in such samples from untreated rats with PCP [unpublished 
observations]. Despite these observations, administration of a-TNF-abs together with 
standard dosages of cotrimoxazole did not affect inflammatory parameters. Therefore, 
TNF-α may either not play a role in our PCP model or local TNF activity was not 
adequately neutralized by our interventions. Further studies may be required to evaluate 
administration of TNF-α or a-TNF by aerosol rather than by instillation or by different 
dosages or frequency of administration. 
Finally we could confirm findings by other authors that lower than usual doses of 
cotrimoxazole are remarkably effective in elimination or suppression of P.carinii [9,13]. 
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Chapter 8 
GENERAL DISCUSSION AND CONCLUSIONS 
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The objective of the study was to increase insight in the role of cytokines in the pathoge-
nesis of PCP. Since in a focal infection such as pneumonia, local effects of cytokines are 
expected to be important and possible different from systemic effects, we compared cy-
tokine patterns in various compartments. We did in-vitro experiments, followed by 
descriptive studies on cytokine patterns in different PCP models and finally explored the 
effects of cytokine modulation. 
I. IN-VITRO EXPERIMENTS 
We could not confirm earlier reports that P. carinii cysts are able to induce in-vitro 
production of cytokines in peripheral blood mononuclear cells and alveolar cells [1-2]. 
Our results however corroborate those of Helmke and Hidalgo, who also reported failure 
of in-vitro TNF-a production on exposure to P.carinii [3]. Differences in cell selection, 
P. carinii preparations and culture media might be partly responsible for these divergent 
results. 
II. IN-VIVO CYTOKINE PROFILES 
A. Local and systemic cytokine concentrations in human and rat PCP 
Cytokines in BAL and lung homogenates - In BAL fluid of HIVpos and HIVneg patients 
with PCP, concentrations of immunoreactive pro-inflammatory cytokines are generally 
higher than in healthy controls, but only significant for IL-lß in HIVpos patients (184 ± 
47 pg/ml versus <20 pg/ml, p=0.01), and for TNF-a in HIVneg patients (551 ± 322 
pg/ml versus <20 pg/ml, ρ=0.02). Cytokine ratios are shown in Fig.lA. Increased 
concentrations of pro-inflammatory cytokines are also found in rats with PCP: with 
increased concentration of IL-lß nd IL-6 in respectively lung homogenates and BAL fluid 
(data not shown). Thus, at least one of the pro-inflammatory cytokines is present at the 
site of infection, although this is not always the same mediator. Why different pro-
inflammatory cytokine are present in BAL in the various PCP models (HIVpos patients, 
1 J HIVPOS UZZI HIVNEQ m ί ί HIVNEQ 
Fig.l Cytokine ratios in BAL (ΙΑ) and plasma (IB) during the acute phase of PCP Ratios represent 
median concentration of patients 
median concentration of controls 
Healthy HIVneg volunteers were controls for BAL concentrations in HIVncg and HIVpos patients (1A). 
Control for plasma data was own plasma from the patients after recovery (IB) 
immunosuppressed HIVneg patients and steroid treated rats) needs further study. The 
explanation for these differences is most likely multifactorial and may reflect different 
underlying immune deficiencies or disease stages. 
It is remarkable that TNF-a, which is most frequently mentioned in relation to HIV and 
P.carinii, is only increased in BAL in HIVneg patients. It is however in accordance with 
the results of Kandil et al.[4]. They show that HIV infection modulates the response to 
P.carinii; monocyte-derived macrophages in-vitro infected with HIV and co-incubated 
with P.carinii, produce less TNF-a and IL-lß as compared to non-HIV infected cells. In 
our rat model the use of a bio-assay could account for the undetectable levels of TNF-a 
in BAL and lung homogenates. 
In some of the HIVpos patients the increased concentration of IL-lß is accompanied by a 
local increase of IL-IRA. High TNF-a levels in BAL fluid of HIVneg patients are not 
accompanied by increased concentrations of sTNF-receptors, IL-IRA concentrations are 
however significantly increased. 
Plasma cytokines - Circulatory pro-inflammatory cytokine concentrations during the acute 
phase of PCP are not different from those after full recovery in both patients and rats 
(Fig. IB). However, in the acute phase of PCP, plasma concentrations of anti-inflamma-
tory mediators IL-1RA (p=0.01) and sTNF receptors, especially P75 (p=0.04), are 
significantly increased in respectively HIVpos and HIVneg patients. 
Thus in PCP, pro-inflammatory cytokines are more prominently present at the site of 
infection, while anti-inflammatory mediators are relatively higher in the circulation 
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IL-1RA IG anti-Inflammatory cytokine·? 
Fig.2 Compartmentahzation of cytokine profiles in lungs (alveolar space and interstitmm) and blood m patients and 
rats with Pneumocystis carinii pneumonia. The predominant cytokines at the various sites under the three conditions 
are schematically indicated It can be concluded that pro-inflammatory cytokines dominate at the focus of infection, 
while anti-inflammatory cytokines are more prominently present in the circulation. 
(Fig.2). It is tempting to speculate that the high concentrations of anti-inflammatory 
mediators in the circulation ensure that the effect of the pro-inflammatory cytokines 
remains limited to the site of infection. The host is subsequently protected from the del-
eterious systemic effects of pro-inflammatory cytokines, including damage to the 
endothelium, shock and mortality. In the lungs, pro-inflammatory cytokines are conside-
red important, at least at the start of the infection, to activate the host response systems in 
order to eliminate or directly kill P.cannii. The fact that in both patient groups the 
increase of one particular pro-inflammatory cytokine in BAL is accompanied by an 
increase of its specific inhibitor in plasma supports this hypothesis. 
The high concentration of IL-1RA in BAL fluid of HIVneg and some HIVpos patients 
may be explained by the necessity to counteract also locally the possible deleterious 
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effects of the pro-inflammatory cytokines. 
B. Ex-vivo cytokine production by alveolar cells and whole blood 
Alveolar cells - In the HIVpos patients with PCP, LPS-stimulated production of pro-
inflammatory cytokines is not affected, while production in HIVneg patients is reduced. 
In the rats, pro-inflammatory cytokine production slowly declines to profound suppression 
over a 6 weeks period; however at week 4 a higher response is found in PCP rats as 
compared to control steroid rats. Stimulated as well as spontaneous production of IL-IRA 
is increased in HIVpos patients and reduced in HIVneg patients with PCP. 
Whole blood cultures - LPS-stimulated pro-inflammatory cytokine production in whole 
blood cultures is suppressed in the acute phase of PCP, in patients as well as rats. IL-
1RA production is intact both in HIVpos as in HIVneg patients. 
The data on in-vivo cytokine concentrations in BAL and blood and in-vitro cytokine 
production in whole blood are to some extent similar in all PCP patients and rats. PCP is 
therefore likely to be primarily responsible for these findings. However, ex-vivo pro-
duction of cytokines by alveolar cells differs substantially between the PCP groups. This 
suggests that underlying immunoregulatory defects (HIV infection, steroids) play an 
important role in these differences (see below). The differential regulation of alveolar 
macrophages and peripheral blood cells shown in patients and rats, is in accordance with 
other studies. Differentiation of blood monocytes into alveolar macrophages changes their 
capacities to release pro-inflammatory cytokines and their inhibitors (5-8). In general, 
blood monocytes are higher producers of IL-lß, while alveolar macrophages produce 
relatively more IL-1RA (5). Our results, especially in HIVpos patients are in line with 
these observations. Due to their localisation, alveolar macrophages are continuously 
exposed to external stimuli. It may be conceivable that they produce more readily IL-1RA 
to reduce potential damage by pro-inflammatory cytokines. This theory, however, does 
not hold for the TNF family. Nicod reports that blood monocytes are higher producers of 
the sTNF-receptor P75, while alveolar macrophages produce more TNF-a. We could 
confirm the higher TNF-a production by alveolar cells, but sTNF receptors could hardly 
be found in our whole blood cultures. 
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III. THE EFFECT OF CORTICOSTEROIDS AND HIV INFECTION ON CYTOKINE 
PROFILES 
Corticosteroids - Eight out of 23 HIVpos patients received corticosteroids 2-24 hours 
before BAL. Concentrations of cytokines in BAL and blood of these 8 patients were the 
same as of those not treated with corticosteroids. Similarly, cytokine concentrations in 
BAL and blood of HIVneg patients were also not influenced by adjunctive corticosteroid 
therapy. In the animal model the same was found, i.e. in rats corticosteroid treatment did 
not affect cytokine concentrations in lung or blood. Thus, although corticosteroids are 
well known for major anti-inflammatory activity, by inhibiting NF-KB activity, we did 
not find an effect on cytokine concentrations in BAL or plasma in humans or rats infected 
with PCP. Similarly, corticosteroids did not immediately suppress pro-inflammatory 
cytokine production by alveolar cells in HIVpos patients and rats. Suppression of cytokine 
production by alveolar cells was however seen in the rat after 4-6 weeks of steroid 
administration. And in HIVneg patients with PCP, all of them on longstanding steroid 
treatment, cytokine production by alveolar cells was profoundly suppressed. 
In whole blood cultures, in patients as well as in rats, steroids had an immediate 
significant suppressive effect on cytokine production. This differential effect of steroids 
on cytokine production in alveolar cells and blood is in accordance with the findings of 
Strieter et al, who showed in in-vitro experiments that the inhibitory effects of steroids on 
TNF-a production was more pronounced in peripheral blood monocytes than in alveolar 
macrophages [11]. 
Thus, administration of corticosteroids immediately reduces ex-vivo pro-inflammatory 
cytokine production in whole blood cultures, while production by alveolar cells became 
only apparent after some weeks. In-vivo concentrations of cytokines in BAL fluid and 
blood did not seem to be affected by corticosteroid administration. 
HIV infection - HIV infection per se results in high plasma concentrations of pro-
inflammatory cytokines and s-TNFR's and increased spontaneous pro-inflammatory ex-
vivo cytokine production. These findings are in accordance with those of others [12-18]. 
PCP does not further increase plasma concentrations of pro-inflammatory cytokines. 
These findings are not in concert with the studies by Jones et al [19]; they report that 
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increased plasma concentrations of TNF-a in HIV infected persons were caused by 
opportunistic infections, such as PCP, and not by the HIV infection per se. 
IV. CORRELATIONS BETWEEN CYTOKINE CONCENTRATIONS AND 
SEVERITY OF INFECTION 
Cytokine concentrations neither correlate with disease activity in patients nor with 
inflammatory parameters in the rat model. This is in contrast with findings of Benfield et 
al who show a significant correlation between the levels of chemotactic IL-8 and severity 
of infection, as determined by P02 and BAL neutrophilia [20,21]. The explanation for 
this discrepancy remains speculative. Possibly the time of sampling is important. It has 
been reported that the concentrations of IL-8 persist for longer than that of TNF-a and 
IL-lß [22]. 
We could confirm that the clinical pictures of PCP in HIVpos and HIVneg patients show 
differences [23,24]. HIVpos patients show a more slowly developing clinical disease and 
are less ill than HIVneg patients. They generally had a longer duration of symptoms 
(mean 5 versus 2.8 days) and higher P02 (8.6 kPa versus 8.2 kPa). The percentage of 
patients admitted to the intensive care unit as well as the mortality was lower in HIVpos 
patients than in HIVneg patients with PCP (9% versus 40% and 9% versus 30% 
respectively). Increased concentrations of TNF-a, with concomitantly unchanged 
concentrations of sTNF-receptors in BAL in the HIVneg patients is in agreement with this 
finding. In the HIVpos patients the inflammatory activity by increased concentration of 
IL-lß in BAL may be more adequately neutralized by the presence of the high IL-IRA 
concentrations. 
V. CYTOKINE INTERVENTIONS 
Intratracheal TNF-a early in the infection in addition to suboptimal cotrimoxazole was not 
synergistic in eradication of P.carinii organisms and intratracheal administration of a-
TNF-antibody later in the infection did not reduce inflammation. 
It is well appreciated that only one carefully chosen experimental condition has been 
tested. As is often the case with negative results, we cannot exclude that other doses, 
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timing or frequency of administration of TNF-a and/or a-TNF-antibody and assesment of 
inflammation parameters on an earlier time point after start of therapy would have 
produced different results. So far, however, we have no evidence that modulation of 
TNF-a reactivity changes the course of a PCP in our rat model. 
CONCLUSION 
In conclusion, in the acute phase of PCP local cytokine profiles differ from those in the 
circulation: pro-inflammatory cytokines dominate in the lung and anti-inflammatory 
mediators in the circulation. In focal infections the local balance between pro- and anti-in­
flammatory cytokines influences severity of disease. Steroids have immediate profound 
effects on cytokine production in blood, and not in alveolar cells. Lower than usual doses 
cotrimoxazole can be effective in PCP. Intratracheal administration of TNF-a early or 
anti-TNF later in the infection does not influence P.carinii load or inflammation parame­
ters in our test conditions. 
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SUMMARY 
In Chapter one, we briefly summarized the data from literature showing that pro-inflam-
matory cytokines are involved in PCP. We explained our objectives and gave the 
arguments why we decided to explore cytokine responses in the different compartments, 
i.e. lung and blood. 
In Chapter two, a rat model was presented for establishment of PCP. A consistent and 
reproducible PCP model was developed in corticosteroid-treated rats. IgG scintigraphy 
and '"Indium biodistribution are sensitive and quantitative methods to assess the severity 
of PCP. Combining data on lung/body weight ratio, P.carinii density score in Giemsa 
stained impression smears and n,Indium-IgG biodistribution is a good method for 
monitoring course and severity of PCP. 
In Chapter three we studied the capacity of Pneumocystis carinii to induce cytokine 
production in-vitro. In our system, Pneumocystis carinii were not able to stimulate in-
vitro cytokine production by alveolar cells or peripheral blood cells. 
In Chapter four we studied pro-inflammatory cytokine profiles in the rat PCP model. 
Cytokine profiles were assessed at 2-weekly intervals. IL-Iß was elevated in lung 
homogenates and IL-6 in BAL fluid, whereas IL-lß, IL-6 and TNF-a were not increased 
in plasma. In rats with PCP elevated pro-inflammatory cytokines concentrations were 
restricted to the lung compartments. 
Corticosteroids did not significantly affect cytokine concentrations, but showed profound 
inhibitory effects on ex-vivo cytokine production. The LPS-stimulated cytokine production 
by alveolar cells gradually decreased during the 6 weeks after start of the steroid injecti-
ons, while the production in whole blood cultures was immediately and completely 
suppressed. 
In Chapter five the question of cytokine profiles in HIVneg patients with PCP was 
addressed. TNF-a was detectable in BAL fluid during the acute phase of PCP in HIVneg 
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patients. At the same time, plasma concentrations of pro-inflammatory cytokines were 
low, and of anti-inflammatory mediators were high. Thus, in HIVneg patients with PCP, 
concentration of the pro-inflammatory cytokine TNF-a is increased in BAL, while anti-
inflammatory mediators dominate in blood. Ex-vivo production of pro-inflammatory 
cytokines was suppressed in blood as well as in alveolar cells during the acute phase of 
PCP, while production of IL-1RA was suppressed in alveolar cells but preserved in 
blood. Correlations between inflammatory mediators and disease activity were not found. 
In Chapter six investigations were presented on cytokine profiles in HIVpos patients with 
PCP. We showed that IL-lß was increased in BAL of HIVpos patients with PCP as 
compared to healthy controls. In plasma of HIVpos patients, higher concentrations of IL-
1RA were found during acute PCP compared to levels after recovery. Ex-vivo production 
of pro-inflammatory cytokines was suppressed in whole blood cultures during PCP, 
whereas IL-1RA production by alveolar cells as well as in whole blood cultures was 
increased. Corticosteroids did not seem to affect cytokine concentrations in BAL or 
blood, nor did they seem to suppress production in alveolar cells. In whole blood cultures 
however, the LPS-stimulated production was significantly suppressed for IL-lß and for 
IL-6. Correlations between inflammatory mediators and disease activity were not found. 
We concluded that in PCP pro-inflammatory cytokines are predominantly present in BAL, 
whereas anti-inflammatory mediators are more prominent in blood. 
In Chapter seven we examined effects of local administration of TNF-a and anti-TNF 
combined with cotrimoxazole in experimental Pneumocystis carinii pneumonia. Intratra-
cheal TNF-a in the first weeks after infection in addition to suboptimal cotrimoxazole was 
not synergistic in eradication of Pneumocystis carinii. Treatment with intratracheal anti-
TNF in the 5th and 6th week after infection combined with standard dose cotrimoxazole 
did not reduce inflammation. 
In Chapter eight we summarized the common features of cytokine profiles in the 
different models and conclude that in PCP a predominance of pro-inflammatory cytokines 
is seen at the site of infection, while anti-inflammatory cytokines are more prominent in 
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the circulation. We hypothesized that the high concentrations of anti-inflammatory 
cytokines in the circulation ensure that the effect of the pro-inflammatory cytokines 
remains limited to the site of infection, thereby protecting the host from deleterious 
systemic effects of pro-inflammatory cytokines. The influence of steroids and HIV 
infection on the observed cytokine profiles, the absence of correlation between disease 
activity and cytokine patterns and the failure to influence disease activity by local TNF 
modulation were discussed. 
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SAMENVATTING 
Pneumocystis carinii pneumonie (PCP) is een vaak voorkomende en ernstige opportunisti-
sche infectie in HlV-seropositieve (HIVpos) patiënten. Ook HIV-seronegatieve (HlVneg) 
patiënten, met name gebruikers van corticosteroiden, kunnen een ernstige PCP ontwikke-
len. Aan de cytokinen interleukine-lß (IL-lß), interleukine-6 (IL-6) en tumor necrosis 
factor-α (TNF-a) wordt een belangrijke rol toegedacht in de Pathogenese van bacteriële 
en parasitaire infecties. De precieze rol van deze cytokinen in de pathofysiologie en de 
Symptomatologie van PCP is echter niet duidelijk. 
Andere onderzoekers lieten zien dat Pneumocystis carinii (P.carinii) in staat is om de in-
vitto productie van TNF-a door alvéolaire macrophagen te stimuleren. TNF-a zou in 
staat zijn om P.carinii direct te doden. Chen en co-werkers toonden in een muizen PCP 
model aan dat TNF-a, IL-lß en IL-6 vroeg in de infectie nodig waren om P.carinii uit te 
roeien. In meerdere proefdier- en patientenstudies werd aannemelijk gemaakt dat 
alvéolaire macrophagen in PCP geactiveerd zijn en in staat zijn tot een verhoogde produc-
tie van TNF-a. 
Daar cytokinen voornamelijk lokaal werkzaam zijn, is het te verwachten dat de cytokine 
patronen op de plaats van de ontsteking (in geval van PCP, in de long) verschillen van die 
in de circulatie. Men zou tevens kunnen veronderstellen dat in de long, binnen de 
verschillende compartimenten (alvéolaire of interstitiele ruimten) het cytokine patroon niet 
hetzelfde is. Immers fenotype en functie van macrofagen, hoofdproducenten van TNF-a 
en IL-lß, worden beïnvloed door het micromilieu. 
Vrijwel alle mensen en dieren ademen geregeld P.carinii organismen in. Een pneumonie 
ontstaat echter alleen als er sprake is van een immuunstoomis. Immuunstoomissen op zich 
hebben óók invloed op cytokine patronen. HIV infectie is geassocieerd met toegenomen 
pro-inflammatoire cytokine productie, terwijl corticosteroiden over het algemeen een pro-
inflammatoire cytokine productie onderdrukken. Bij het interpreteren van cytokine 
patronen in PCP moet hiermee rekening gehouden worden. Wat wordt veroorzaakt door 
de PCP en wat door de onderliggende immuunstoomis? 
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STUDIE OPZET 
Het doel van ons onderzoek was om meer inzicht te krijgen in de rol van cytokinen in 
PCP. De vraag of cytokine concentraties en productie in de verschillende compartimen-
ten (long en bloed) van elkaar verschilden, stond daarbij centraal. Wij onderzochten 
daartoe in-vivo concentraties en ex-vivo productie van een aantal cytokinen in verschillen-
de compartimenten in dieren en patiënten met verschillende onderliggende immuunstoor-
nissen. 
In een ratten PCP model, waarbij PCP werd geïnduceerd door corticosteroiden, werden 
immunoreactief IL-Iß en bioactief TNF-α en IL-6 bepaald. De cytokine concentraties 
werden gemeten in plasma, longspoelsel (broncho-alveolaire lavage, BAL) en longhomo-
genaten. 
Twee groepen patiënten met PCP werden onderzocht, HIV-seronegatieve patiënten, die 
Prednison gebruikten (voornamelijk niertransplantatie patiënten) en 23 HIV-seropositieve 
patiënten. De onderzochte cytokinen in patiënten waren IL-Iß, TNF-α, IL-6, en de 
remmers van IL-lß en TNF-α, respectievelijk IL-1 receptor antagonist (IL-1RA) en de 
oplosbare TNF receptoren (sTNF-R). Cytokine concentraties werden bepaald in plasma en 
in longspoelsel. 
Daarnaast werd zowel in patiënten als in ratten de ex-vivo productie door alvéolaire cellen 
en in volbloedkweken gemeten. De ex-vivo productie is een maat voor het vermogen van 
cellen om cytokinen te produceren. 
In het rattenmodel werd ook de kinetiek van de cytokinen bestudeerd. Meer inzicht in de 
rol van de onderliggende immuunstoornis (HIV infectie, corticosteroid gebruik) werd 
verkregen door vergelijking van cytokine patronen in de verschillende modellen, met 
verschillende controlegroepen en in een beperkt aantal patiënten vlak voor en vlak na 
toediening van corticosteroiden. 
Tenslotte werden enkele interventie-experimenten verricht met intratracheaal toegediend 
TNF-α en een polyklonaal anti-TNF antiserum in de hoop door lokale cytokine modulatie 
het beloop van de infectie te beïnvloeden. 
In hoofdstuk 1, de introductie, beschrijven we wat er tot nu toe bekend is over de rol van 
de door ons bestudeerde cytokinen in PCP. We leggen uit waarom we denken dat 
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onderzoek in verschillende compartimenten belangrijk is en beschrijven de studie opzet. 
In hoofdstuk 2 wordt het ratten model beschreven. We zijn erin geslaagd om in ratten 
een consistente en reproduceerbare PCP te induceren, door behandeling met corticosteroi-
den, een eiwitbeperkt dieet en nauw contact met door P.carinii geïnfecteerde ratten. Het 
verloop van de PCP werd gevolgd door op vaste tijdstippen de ernst van de infectie en 
mate van gastheerafweer te bepalen. De emst van de infectie werd bepaald door telling 
van het aantal P.carinii cysten in Giemsa gekleurde deppreparaten van een doorgesneden 
longkwab (P.carinii score). De mate van gastheerweerstand werd gekwantificeerd door 
een histologische ontstekingsscore van paraffine coupes van de long, de ratio 
long/lichaamsgewicht (L/B ratio), "'Indium-IgG (mIn-IgG) biodistributie long/spier ratio, 
en het aantal en de differentiatie van ontstekings cellen in het longspoelsel. Al deze 
parameters correleerden met elkaar. niIn-IgG long/spier (L/M) ratio bleek een goede 
parameter voor de mate van lokale ontstekingsreactie, de infectie werd vroeg gesignaleerd 
en was betrouwbaar te kwantificeren. In de navolgende experimenten kozen wij daarom 
voor P.carinii score, L/B ratio en L/M ratio als parameters om de ernst en het verloop 
van de PCP te volgen. 
In hoofdstuk 3 wordt de vraag behandeld of Pneumocysten in staat zijn om in-vitro 
cytokinen te stimuleren. In onze experimenten bleek dat, in tegenstelling tot wat anderen 
vonden, niet het geval. Verschillen in cel populaties (ongeselecteerde alvéolaire cellen in 
ons systeem ten op ziehte van adhérente cellen in de andere studies), in kweekcondities of 
P.carinii preparaties verklaren mogelijk de verschillen in de uitkomsten. 
In hoofdstuk 4 beschrijven wij de cytokine patronen in het ratten PCP model. 
In Sprague-Dawley ratten met door corticosteroiden geïnduceerde PCP, werden verhoog-
de waarden gevonden voor IL-lß in longhomogenaten en voor IL-6 in BAL vloeistof, 
terwijl de pro-inflammatoire cytokine concentraties in het bloed niet verhoogd waren. Er 
was ter plaatse van de ontsteking, in de long, dus sprake van een pro-inflammatoire 
cytokine status. Door vergelijking van cytokine profielen in met corticosteroiden behan-
delde ratten met en zonder PCP, zagen wij dat corticosteroiden nauwelijks effect hadden 
92 
op de in vivo gemeten cytokine concentraties (zowel lokaal als systemisch). Cor-
ticosteroiden remden echter wel de ex-vivo cytokine productie, een maat voor het 
vermogen van cellen om cytokinen te produceren. Er was daarbij een duidelijk verschil 
tussen de lokale en de systemische cytokine productie. De productie door alvéolaire cellen 
werd geleidelijk in de loop van 6 weken geremd, terwijl de systemische productie (in 
bloedkweken) vrijwel meteen volledig werd geblokkeerd. 
In hoofdstuk 5 beschrijven wij de cytokine profielen in de HlVneg PCP patiënten. Bij 
hen werd in de acute fase van PCP een verhoogde concentratie van TNF-a in BAL 
gevonden. Tegelijkertijd werd in de circulatie een verhoogde concentratie gemeten van 
anti-inflammatoire mediatoren. Na herstel van de PCP daalden de anti-inflammatoire 
cytokine concentraties in het bloed. 
Tijdens de acute fase van PCP bleek de ex-vivo productie van pro-inflammatoire cytok-
inen (in bloed en alveolair celkweken) en die van IL-1RA door alvéolaire cellen onder-
drukt, terwijl de ex-vivo productie van IL-1RA in het bloed behouden bleef. Correlaties 
tussen inflammatoire mediatoren en ziekte-activiteit kon niet worden aangetoond. Ook in 
dit model zagen wij dus een pro-inflammatoire cytokine status in de long tijdens de acute 
fase van PCP en dit ging gepaard met een duidelijke dominantie van de anti-inflammatoire 
mediatoren in de circulatie. 
De cytokine profielen in de HIVpos patiënten met PCP worden beschreven in hoofdstuk 
6. Bij deze patiënten vonden wij verhoogde concentraties van IL-Iß in BAL en ver-
hoogde concentraties IL-1RA in de circulatie tijdens de acute fase van PCP. Tezelfdertijd 
was de ex vivo productie van pro-inflammatoire cytokinen onderdrukt in bloedkweken, 
terwijl de IL-1RA productie juist was verhoogd (zowel in alveolair cellen als in bloed-
kweken). Cytokine concentraties in BAL en bloed leken, net als in het rattenmodel, niet 
te worden beïnvloed door gebruik van corticosteroiden. De LPS-gestimuleerde ex vivo 
productie van 11-1 en IL-6 in bloedkweken werd, conform de bevindingen in het ratten 
model, echter wel duidelijk onderdrukt door het gebruik van corticosteroiden. Ook in de 
HIVpos patiënten werden geen correlaties gevonden tussen cytokine concentraties en 
ziekte-activiteit. 
Onze eindconclusie was dat in PCP bij HIVpos patiënten pro-inflammatoire cytokine 
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overheersen in de BAL, terwijl de anti-inflammatoire mediatoren overheersen in de 
circulatie. 
In hoofdstuk 7 onderzochten wij de effecten van lokaal toegediend TNF-α en anti-TNF in 
combinatie met Cotrimoxazol in het ratten PCP model. Intratracheal TNF-α toegediend 
in het begin van de infectie bleek samen met een suboptimale dosis Cotrimoxazol niet alle 
P.carinii cysten te kunnen uitroeien. En intratracheaal toegediend anti-TNF in combinatie 
met hoge doses Cotrimoxazol later in de infectie verminderde de inflammatoire gast­
heerreacties niet. 
In hoofdstuk 8, de algemene discussie en conclusie, vatten wij de gemeenschappelijke 
kenmerken van de cytokine profielen in de verschillende modellen samen. Wij conclude­
ren dat in PCP een pro-inflammatoire cytokine overwicht wordt gezien in de long, terwijl 
op dat moment in de circulatie de anti-inflammatoire mediatoren domineren. Het lijkt er 
dus op dat de hoge concentratie anti-inflammatoire cytokinen in de circulatie de actie van 
de pro-inflammatoire cytokinen beperkt tot de plaats waar die actie nodig is, de plaats van 
infectie. De gastheer zou zo beschermd worden tegen de schadelijke effecten van de pro-
inflammatoire cytokinen die, wanneer ze in de circulatie in hoge concentratie aanwezig 
zijn, ernstige schade (endotheel schade, shock, mortaliteit) kunnen veroorzaken. Ter 
plekke van de ontsteking lijken de pro-inflammatoire cytokinen, zeker in het begin van de 
infectie, juist nodig om de afweersystemen van de gastheer te activeren ten einde de 
P.carinii te bestrijden. Ook ter plekke van de ontsteking moet waarschijnlijk in het beloop 
van de ziekte, de balans pro- versus anti-inflammatoire cytokinen weer worden hersteld 
om te voorkomen dat de lokale ontstekingsreactie, opgeroepen en onderhouden door pro-
inflammatoire cytokinen, tè veel schade aanricht (oedeem, fibrose). De kinetiek van 
verandering en herstel van die balans pro/anti-inflammatoire cytokinen moet, ter bescher-
ming van de gastheer, lokaal anders verlopen dan in de circulatie. Gegevens over 
cytokine patronen in andere infecties (meningococceninfecties, buiktyfus), bestudeerd door 
onze groep wijzen in dezelfde richting en steunen deze hypothese. 
De invloed van corticosteroiden en HIV infectie op de waargenomen cytokine profielen, 
het ontbreken van correlaties tussen ziekte-activiteit en cytokine patronen en het negatieve 
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resultaat van de interventie-experimenten wordt besproken. 
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Stellingen 
In Pneumocystis carinii pneumonia, pro-inflammatory cytoki-
nes are more prominently present at the site of infection, 
whereas anti-inflammatory mediators dominate In the 
circulation. 
This thesis 
The beneficial effect of steroids on the clinical course of 
Pneumocystis carinii pneumonia is not due to suppression of 
pro-inflammatory cytokine production by alveolar cells. 
This thesis 
Both steroids and severe infection can induce downregulation 
of systemic pro-inflammatory cytokine production. 
This thesis 
Het interpreteren van cytokine profielen In Pneumocystis 
carinii pneumonie lijkt soms op het oplossen van een verge-
lijking met teveel onbekenden. 
' 11 Indlum-IgG blodistributie Is een goede, gemakkelijk te 
kwantificeren parameter voor de mate van lokale ontsteking 
In Pneumocystis carinii pneumonie. 
Dit proefschrift 
P.carinil onderzoek wordt sterk belemmerd door het feit dat 
wij Pneumocysten niet kunnen kweken en het transmissie 
stadium niet kennen. 

7. Als Je Iets niet weet, dan geeft dat te denken. 
8. De vibratie van de stilte reflecteert de essentie van de 
muziek. 
9. Geld steken In wervingscampagnes ten behoeve van de 
eigen universiteit is een door de politiek afgedwongen 
oneigenlijk gebruik van onderwljsgelden. 
10. Het door organisatiebureaus laten oplossen van precaire 
bestuursproblemen Is vooral een modieuze manier van geld 
weggooien. 
11. Een zorgzame overheid hoort niet luchtig te doen over 
luimige zaken. 
12. Onze welvaart doet de wereld stinken. 
13. Academie Departments of Tropical Medicine should be where 
they belong, in the tropics themselves. 
The Lancet 1996;347;629 
14. De kreet 'one world, wanhoop' getuigt van meer werkelijk-
heidszin dan het motto 'one world, one hope', het motief van 
de wereld AIDS conferentie in Vancouver. 
2 december 1996 Roos Perenboom 



